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Erythema nodosum leprosum (ENL) is a painful inflammatory complication of leprosy 
occurring in 50% of lepromatous leprosy patients and 5–10% of borderline lepromatous 
patients. It is a significant cause of economic hardship, morbidity and mortality in leprosy 
patients. Our understanding of the causes of ENL is limited. We performed a systematic 
review of the published literature and critically evaluated the evidence for the role of neu-
trophils, immune complexes (ICs), T-cells, cytokines, and other immunological factors that 
could contribute to the development of ENL. Searches of the literature were performed 
in PubMed. Studies, independent of published date, using samples from patients with 
ENL were included. The search revealed more than 20,000 articles of which 146 eligible 
studies were included in this systematic review. The studies demonstrate that ENL may 
be associated with a neutrophilic infiltrate, but it is not clear whether it is an IC-mediated 
process or that the presence of ICs is an epiphenomenon. Increased levels of tumor 
necrosis factor-α and other pro-inflammatory cytokines support the role of this cytokine 
in the inflammatory phase of ENL but not necessarily the initiation. T-cell subsets appear 
to be important in ENL since multiple studies report an increased CD4+/CD8+ ratio in 
both skin and peripheral blood of patients with ENL. Microarray data have identified new 
molecules and whole pathophysiological pathways associated with ENL and provides 
new insights into the pathogenesis of ENL. Studies of ENL are often difficult to compare 
due to a lack of case definitions, treatment status, and timing of sampling as well as the 
use of different laboratory techniques. A standardized approach to some of these issues 
would be useful. ENL appears to be a complex interaction of various aspects of the 
immune system. Rigorous clinical descriptions of well-defined cohorts of patients and a 
systems biology approach using available technologies such as genomics, epigenomics, 
transcriptomics, and proteomics could yield greater understanding of the condition.
Keywords: erythema nodosum leprosum, leprosy, type 2 reaction, immunology, systematic review, TNF-α, 
neutrophils, immune complexes
iNTRODUCTiON
Leprosy is an infectious disease predominantly of skin and peripheral nerves, caused by the obligate, 
intracellular, acid-fast bacillus Mycobacterium leprae. The organism shows tropism for macrophages 
and Schwann cells (1). The pathology and clinical phenotype of leprosy is determined by the host 
immune response to M. leprae (2). Patients develop leprosy on a clinical spectrum ranging from 
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tuberculoid leprosy through borderline forms to lepromatous 
leprosy (LL) of the Ridley–Jopling classification (2). Patients 
with tuberculoid leprosy have a strong cell-mediated immune 
response to M. leprae limiting the disease to a few well-defined 
skin lesions and/or peripheral nerves (3). Patients with LL have 
absent cellular immunity and high titers of antibodies against M. 
leprae, which are not effective in controlling the bacilli (4).
Multi-drug therapy (MDT) is highly effective for treating the 
infection (1). However, despite this, 30–40% of patients with lep-
rosy undergo immune-mediated inflammatory episodes such as 
Type 1 reactions (T1R) and erythema nodosum leprosum (ENL 
or Type 2 reactions) (5).
ENL is a painful inflammatory complication occurring in 
50% of LL patients and 5–10% of borderline lepromatous leprosy 
(BL) patients particularly those with a bacterial index above 4 
(6), whereas T1R predominantly affect those with borderline 
tuberculoid leprosy (BT), mid-borderline, and BL leprosy. 
Individuals with ENL present crops of painful, erythematous 
skin nodules with systemic symptoms of fever and malaise (6). 
ENL is a multisystem disorder and other organ involvement 
includes iritis, arthritis, lymphadenitis, orchitis, and neuritis 
(6). The histology of ENL skin lesions often shows an intense 
perivascular infiltrate of neutrophils throughout the dermis 
and subcutis (7) and vasculitis with edema of the endothe-
lium together with granulocyte infiltration of vessels walls 
(8–10). However, not all ENL skin biopsies show evidence of 
vasculitis (10–13).
ENL is usually treated with high-dose oral corticosteroids or 
thalidomide if it is available and affordable. High doses of clo-
fazimine are also commonly used (6). Treatment often lasts for 
many months or years. Few patients experience a single episode 
of acute ENL with the majority experiencing recurrent or chronic 
disease (6, 14). Prolonged use of oral corticosteroids is associated 
with multiple adverse effects (6). Our group has demonstrated 
that ENL results in significant economic hardship, morbidity, and 
mortality in patients (15, 16).
ENL is often described as a neutrophilic immune-complex-
mediated condition, while there is evidence that T-cells further 
complicate the immunopathology. Elevated levels of certain 
cytokines such as tumor necrosis factor (TNF)-α and other 
immunological factors have been associated with episodes 
of ENL.
We performed a systematic review of the published litera-
ture and critically evaluated the current evidence for the role 
of immunological factors that have been associated with the 
ENL. We created a flowchart showing our search strategy by 
identifying the studies to be included in this systematic review 
(Figure  1). We divided the systematic review into sections 
according to the immune parameter under investigation 
including neutrophils, immune complexes/complement, 
T-cells, and cytokines. Furthermore, we sought to identify pos-
sible methodological issues that might account for discrepan-
cies between studies and to make recommendations for future 
immunological studies of ENL. The studies that we considered 
to have the most important findings are discussed in detail, 
while all the studies included in the review are summarized in 
the comprehensive tables.
MeTHODOLOGY
The Preferred Reporting Items for Systematic review and Meta-
Analysis Protocols (PRISMA-P) 2015 guideline was used to 
prepare this systematic review (17).
Searching
Searches of the literature were performed up to 31st October 2016 
in PubMed by the first author. Keywords used were: Hansen* OR 
Type 2 OR Type II OR leprosy OR lepra*, AND reaction OR ery-
thema nodosum leprosum OR ENL. The references included in 
each study were also checked for potentially relevant publications.
inclusion Criteria
Immunological studies in PubMed, independent of published 
date, using samples from patients with ENL were included. 
Human samples including sera, peripheral blood mononuclear 
cells (PBMC), skin biopsies, or any other tissue were eligible for 
inclusion. Publications in languages other than English were 
translated.
An immunological study was defined as any study of the 
molecular and cellular components that comprise the immune 
system, including their function and interaction.
Results of Search
The search in PubMed revealed 95,771 records, which were nar-
rowed down by using restrictions, species (humans), and search 
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fields (title/abstracts), leading to 20,174 records (Figure  1). 
A total of 19,846 studies were excluded by title because they did 
not address leprosy or ENL. Others were excluded because they 
did not include samples from ENL patients or they were clinical 
trials, epidemiological studies, case reports, review papers, com-
mentaries, histological studies, genetic studies, and investigations 
of non-immunological factors. The abstracts of the remaining 328 
titles were reviewed and a further 69 studies were excluded due to 
the same considerations.
The 259 papers were obtained full text of which 113 were 
excluded for the reasons described above. When there was doubt 
about studies, the first and second author agreed on whether they 
should be included in the systematic review. Data were extracted 
from the 146 eligible studies. Of these 146 eligible studies, 5 stud-
ies investigated the role of neutrophils in ENL, 28 studies inves-
tigated the role of immune complexes and complement in ENL, 
44 studies investigated the role of T-cells in ENL, and 49 studies 
investigated the role of cytokines in ENL, of which 30 investigated 
the role of TNF-α in ENL. Sixty-four studies investigated the role 
of other immunological factors in ENL.
Data Synthesis and Analysis
Data extraction from each study was conducted by the first 
author. Structured forms were designed for each of the five 
main sections of the systematic review: neutrophils, immune 
complexes and complement, T-cellular immunity, cytokines, 
and other immunological molecules or factors involved in the 
pathophysiology of ENL. Data were collected on the setting 
(study location and country of affiliation of the authors), study 
design and characteristics of the subjects (ENL case definition, 
study population included, number of patients with ENL, 
control subjects, timing of sampling, treatment for ENL and 
leprosy treatment), study measures and main findings reported 
by the study authors. A study could include multiple measures 
and therefore be part of more than one section of the systematic 
review.
wHAT iS THe ROLe OF NeUTROPHiLS iN 
eNL?
Neutrophils are the predominant immune cell population in 
human blood and provide protection through phagocytosis, gen-
eration of neutrophil extracellular traps (NETs), and secretion of 
antimicrobial peptides (18). Recent evidence supports a role for 
neutrophils in the orchestration of adaptive immunity, engaged 
with lymphocytes and antigen-presenting cells (APCs) (19).
Neutrophils are considered to be the histological hallmark of 
ENL (7, 13). The histology of ENL skin lesions shows an intense 
perivascular infiltrate of neutrophils throughout the dermis and 
subcutis (7, 13). However, not all ENL lesions are characterized by 
the presence of neutrophils (12, 20–22) and the timing of biopsies 
appears crucial in detecting neutrophil infiltration (7, 23). A 
study of skin biopsies of ENL lesions within 72 h of onset showed 
a predominance of neutrophils in 30.4% of biopsies. Skin biopsies 
performed between 9 and 12 days showed neutrophils in 1.6% of 
specimens and increasing numbers of lymphocytes, plasma cells, 
and histiocytes (7). Neutrophils may precede the chemotaxis of 
lymphocytes into ENL lesions, but it is unclear why neutrophils 
are not always present in the initial stage of ENL.
The study by Lee et al. used DNA microarray and bioinfor-
matic pathway analysis of gene expression profiles in skin biopsies 
obtained from six patients with ENL compared to seven LL con-
trols (24). They identified 57 functional groups and 17 canonical 
pathways characteristic of ENL. Their striking finding was the 
“cell movement” functional pathway composed of 188 genes. 
From the list of genes of the “cell movement” pathway, 25 were 
identified to be involved specifically in neutrophil recruitment 
including the genes for P-selectin, E-selectin, and its ligands (24). 
Using immunohistochemistry, they showed that E-selectin was 
expressed in a vascular pattern and at higher levels in ENL skin 
lesions than in LL, although this was not quantified (24). They 
described an integrated pathway of TLR2/Fc Receptor activation 
triggering induction of interleukin (IL)-1β, which together with 
interferon (IFN)-γ, induced E-selectin expression on endothelial 
cells and neutrophil migration and adhesion to endothelial cells 
(24). Interestingly, thalidomide inhibited this neutrophil recruit-
ment pathway (24).
A recent Brazilian study reported that surface CD64 (FcγRI) 
expression on circulating neutrophils increased significantly 
during ENL, while BL/LL patients without ENL had lower levels 
of CD64 (25). In addition, CD64 expression on neutrophils 
decreased after thalidomide treatment (25). Moreover, the higher 
levels of CD64 on circulating neutrophils were correlated with 
disease severity (25). This study demonstrated the potential of 
CD64 as an early biomarker for ENL and as a marker of severity 
(25). CD64 (FcγRI) is the high-affinity receptor for monomeric 
IgG1 and IgG3 (26). While resting neutrophils express low levels 
of CD64 (26), an increase of neutrophil CD64 surface expression 
is observed in certain Gram negative bacterial infections (27) and 
has been associated with the prognosis of disseminated intravas-
cular coagulation during sepsis (28). The authors suggested that 
CD64 upregulation during ENL could be due to the presence 
of inflammatory cytokines such as IFN-γ and GM-CSF (29) or 
certain intracellular components of fragmented M. leprae bacilli 
following treatment with MDT (25). This was further supported 
by clinical studies showing that although ENL may also occur 
before initiation of treatment with MDT, the incidence of ENL is 
higher during treatment with MDT (5, 30).
Studies in the 70s tried to assess the polymorphonuclear leu-
kocyte (PMN) functions in different forms of leprosy and ENL, 
investigating whether ENL is associated with PMN activation (31, 
32). The nitro blue tetrazolium (NBT) test that measures PMN 
activation was increased in six patients described as LL with 
leprosy reactions compared with non-reactional leprosy patients 
(from across the leprosy spectrum) and healthy controls (31). In 
addition, LL patients with reactions had lower PMN activation 
when treated with steroids or thalidomide, although this was not 
significant (31). Another study found the resting NBT levels in 
different leprosy groups (tuberculoid, lepromatous, and patients 
with ENL) to be within normal limits (32). However, the sera 
from patients with ENL produced significantly increased levels 
of PMN activation as measured by the NBT test when incubated 
with PMN cells from healthy controls and patients with ENL 
TABLe 1 | Studies of neutrophils in eNL.
Reference; 
study site(s)
Study 
population
Timing of 
screening
MDT 
status
eNL 
treatment
Type of 
samples
Measures Findings
Goihman-Yahr 
et al. (31); 
Venezuela
6 ENL, 32 
BL/LL, 6 
treated ENL, 9 
indeterminate, 
11 tuberculoid, 
14 HC
ND ND Excluded 
patients on 
steroids except 
treated ENL
Peripheral 
blood 
neutrophils
Reduction of nitro blue 
tetrazolium (NBT)
Increased neutrophil activation in ENL
Serum Neutrophil response to 
endotoxin
Lower neutrophil activation after ENL treatment
Plasma Effect of adding sera 
and plasma from ENL to 
neutrophils of HC
Sera from ENL did not activate neutrophils 
from HC
Sher et al. 
(32); South 
Africa
8 ENL, 17 BT, 11 
lepromatous, HC
ND ND ENL not 
receiving 
steroids or 
other anti-
inflammatory 
drugs
Peripheral 
blood 
neutrophils
PMN leukocyte motility Defect in random migration, chomotaxis, and 
chemokinesis in both ENL and lepromatous 
patients
Serum Reduction of nitro blue 
tetrazolium (NBT)
Reconstitution of PMN leukocytes from HC 
and ENL with sera from ENL led to increased 
neutrophil activation
Oliveira et al. 
(33); Brazil δ
10 BL/LL:6 ENL, 
10 HC
ND On MDT ND Peripheral 
blood 
neutrophils
Apoptosis Increased apoptosis in ENL
DNA fragmentation 
extracted from 
neutrophils
Stimulated neutrophils secrete IL-8 and tumor 
necrosis factor (TNF)-α
TNF-α and IL-8
Lee et al. (24); 
USA ε
6 ENL, 7 LL ND ND ND Skin Microarrays and gene 
expression analysis
Genes involved in neutrophil recruitment 
identified
Ability of HUVEC to bind 
neutrophils from HC
Thalidomide diminished neutrophil binding to 
HUVECs stimulated with cytokines
Schmitz et al. 
(25); Brazil ε
62 leprosy: 22 
ENL, 16 HC
ENL: 
before and 
7 days after 
thalidomide
Patients 
before 
and after 
MDT
ENL: before 
and after 
thalidomide
Peripheral 
blood 
neutrophils
CD64 expression CD64 upregulated on neutrophils during ENL
Higher CD64 on neutrophils from severe ENL
CD64 decreased after thalidomide
β, also in Table 2; γ, also in Table 3; δ, also in Table 4; ε, also in Table 5.
BB, mid-borderline leprosy; BL, borderline lepromatous leprosy; BT, borderline tuberculoid leprosy; ENL, erythema nodosum leprosum; HC, healthy controls; HUVEC, human 
umbilical vein endothelial cells; ICs, immune complexes; LL, lepromatous leprosy polar; ND, not described; PMN, polymorphonuclear; SLE, systemic lupus erythematosus; TB, 
tuberculosis; TT, tuberculoid leprosy polar.
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(32). This finding suggested that sera from ENL patients may 
lead to activation of neutrophils. However, when cell motility 
was studied as a marker of PMN activation using random migra-
tion, chemotaxis, and chemokinesis, all three were defective in 
lepromatous patients with or without complicating ENL (32).
Oliveira et  al. reported the apoptotic rate of neutrophils 
to be greatly accelerated in ENL patients compared to BL/LL 
patients and healthy volunteers (33). Neutrophils isolated from 
leprosy patients (ENL and BL/LL) released TNF-α and IL-8, 
after stimulation with lipopolysaccharide (LPS) or M. leprae 
(33). Interestingly, in vitro TNF-α production by neutrophils was 
inhibited by thalidomide at both 3 and 6 h post-stimulation with 
LPS (33). This supports the role of neutrophils as effector cells 
actively producing pro-inflammatory cytokines and not only as 
migratory cells following chemoattractants.
There is little direct evidence of the actual role of neutrophils 
in ENL, despite the cell being the histological hallmark of ENL. 
There are multiple histological studies showing the presence of 
neutrophils in ENL lesions; however, only five studies investi-
gated whether neutrophils actively take part in ENL as effector 
cells (Table 1). It remains unclear whether the neutrophil initiates 
ENL or is recruited to the site of the affected skin lesion under the 
action of chemokines such as IL-8 secreted by other cell types.
wHAT iS THe ROLe OF iMMUNe 
COMPLeXeS iN eNL?
An IC or antigen-antibody complex is the result of binding 
of one or more antibody molecules with one or more antigen 
molecules (34). The ability of ICs to activate the complement 
system and to interact with a number of cells determines their 
biological properties (35). ICs activate complement pathways 
that opsonize or coat antigen–antibody complexes with large 
numbers of C3 molecules (36). Opsonization facilitates the 
clearance of ICs by the macrophage system (36). By maintain-
ing complexes in solution, the complement allows clearance of 
ICs from their site of formation, minimizing local inflammatory 
consequences (36).
It was hypothesized that ENL is an IC-mediated disorder 
because it has some clinical features in common with the Arthus 
reaction, a type III hypersensitivity reaction that involves the 
deposition of ICs mainly in the vascular walls, serosa, and 
glomeruli and is characterized histologically by vasculitis with a 
polymorphonuclear cell infiltrate (37). The multisystem involve-
ment of ENL resembling autoimmune diseases associated with 
ICs such as systemic lupus erythematosus (SLE), also lends 
credence to this theory.
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Multiple studies have been performed investigating ICs 
in ENL. The widely cited study of Wemambu et  al  included 
17 patients with ENL and six uncomplicated LL controls (37). 
Direct immunofluorescence demonstrated granular deposits of 
immunoglobulin and complement in a perivascular distribution 
in association with a polymorph infiltrate in the dermis of 10 out 
of 17 ENL lesions but not in any lesions of uncomplicated LL 
(37). However, such deposition is not conclusive evidence of ICs. 
The presence of soluble mycobacterial antigen was seen in ICs in 
only 3 out of 17 ENL lesions (37). The authors hypothesized that 
ENL results from the deposition of ICs in and around venules of 
the connective tissue septa of subcutaneous fat (37). The study 
was repeated using 38 patients with ENL and 13 LL controls and 
demonstrated the presence of immunoglobulin, complement, 
and mycobacterial antigen in less than half of the skin biopsies 
from patients with ENL and none of the LL control biopsies (22). 
Non-specific granular deposits of IgG were demonstrated along 
the collagen and elastic fibers in the dermis of all 25 patients with 
ENL in another study, not in any of the 10 LL patient controls (38). 
However, the deposits were not consistently seen in and around 
the blood vessels (38). Later studies in ENL suggest that these ICs 
are extravascular and hence ENL differs from the Arthus reac-
tion (39, 40). These studies taken together provide evidence of an 
association of ICs and ENL but they do not necessarily support 
that ICs are the trigger leading to ENL.
Circulating ICs have been demonstrated in patients across 
the leprosy spectrum (41). The level of circulating ICs in the 
sera of leprosy patients have been measured in many studies 
using different immunological techniques (42–54) of which the 
most commonly used are C1q immunoassays (42, 43, 51). This 
highlights the fact that the use of different immunoassays to 
detect circulating ICs in studies may explain the contradictory 
results. The first study measuring ICs in sera of leprosy patients 
performed C1q immunoassays in samples from LL patients, 
tuberculoid leprosy patients, and healthy volunteers and showed 
that more than 70% of LL patients had demonstrable ICs (43). 
A subsequent study demonstrated increased occurrence of ICs 
in both the sera of ENL patients (80%) and uncomplicated LL 
patients (82%), indicating that the presence of circulating ICs is 
not a characteristic feature of ENL per se (46). Wager et al. ana-
lyzed sera from 135 leprosy patients using the platelet aggregation 
test (PAT) which had been previously suggested to be a sensitive 
detector of IgG complexes in other immunological and infectious 
diseases (55, 56) and concluded that PAT is a sensitive detector of 
IgG complexes peculiar to LL (44). No ICs were detected in the 
sera of leprosy patients using the C1q immunoassay (44).
Specific mycobacterial antigens (41) or antibodies against M. 
leprae antigens (50, 57) have been identified in the ICs derived 
from sera of lepromatous patients with or without ENL. Rojas 
et al. precipitated ICs from sera and detected antibodies against 
phenolic glycolipid-1 (PGL-1) (50) and major cytosolic protein 
of M. leprae (MCP-I). The finding that ICs are composed of anti-
PGL-I and anti-MCP-I antibodies supports the concept that ENL 
is an IC-mediated disorder (50). However, the composition of 
circulating ICs of leprosy controls (combined BT and BL/LL) also 
showed high levels of anti-PGL-I antibodies (50) again suggesting 
that ICs are not specific to ENL.
Dupnik et al. used DNA microarrays to examine gene expres-
sion in PBMC isolated from patients with ENL and matched 
leprosy controls (58). Several components of the classical com-
plement pathway showed increased expression in PBMC from 
patients with ENL: C1qA, B, and C and the complement recep-
tors C3AR1 and C5AR1 (58). Increased intensity of fluorescent 
staining for C1q in skin lesions of ENL compared to BT and BL/
LL controls was demonstrated (58). The finding of increased 
C1q deposition in the skin of ENL does not necessarily mean 
IC deposition has occurred (35). However, these data do support 
activation of the classical complement pathway in ENL, which 
may result from antigen–antibody formation.
Earlier studies in leprosy looked at the role of free complement 
in the sera of lepromatous patients (59). The serum C3 levels were 
decreased in patients with ENL, whereas they were elevated in 
LL controls (60). The low levels of C3 supported the concept that 
ENL is mediated by an antigen-antibody reaction and may be 
due to its utilization during the course of such antigen-antibody 
reactions. Similar decreased serum complement levels have been 
reported in other IC disorders such as acute glomerulonephritis 
(61–63) and acute systemic lupus erythematosus (SLE) (64, 65). 
It has been suggested that ENL is characterized by complement 
hypercatabolism because the level of the C3 breakdown product 
C3d in the sera was increased in 70% of the patients with ENL but 
in only 18% of patients with uncomplicated LL (46).
In other IC-associated diseases such as SLE, systemic 
vasculitides, and nephritis, defective complement-mediated 
solubilization of immune precipitates have been observed (48, 
49, 66). Similarly, leprosy patients with ENL were shown to have 
markedly reduced solubilization levels that remained low for 
3 months, whereas the C3d and circulating IC levels returned to 
baseline levels (48). Circulating ICs isolated from sera across the 
leprosy spectrum as PEG precipitates were shown to be efficient 
activators of the alternative complement pathway. In addition, 
PEG precipitates from BL/LL leprosy patients including those 
with ENL were shown to activate the classical complement path-
way as well (52).
A Brazilian study of 46 patients with ENL investigated the 
association between the MHC class III complement proteins 
C2, BF, C4A, and C4B and leprosy (67). All patients who were 
homozygous for the silent C4B allele (C4B*Q0) and thus C4B-
deficient had ENL (67). Increased frequency of ENL was also 
associated with those who were hemizygous for the C4B*Q0 
allele. The relative risk of patients suffering from ENL carrying 
the C4B*Q0 allele was 5.3 compared with LL patients without 
C4B*Q0 (67). Interestingly, their findings suggested that C4B 
deficiency could play an important role in the abnormal immune 
response to M. leprae and to the lack of IC clearance, leading to 
ENL reactions (67). Hemizygous C4 deficiencies are associated 
with immune complex diseases such as SLE (68).
There is lack of evidence to support a causative role of ICs 
in ENL, which requires the deposition of ICs in tissues, the 
presence of bacterial antigens in these ICs, and the interaction 
of the ICs with the complement cascade and with phagocytic 
cells (35). Although there are 28 studies investigating the pres-
ence of ICs in the skin or circulating ICs in the sera of patients 
with ENL (Table  2), their role remains uncertain. It is unclear 
TABLe 2 | Human studies on eNL investigating immune complexes and complement.
Reference; 
study site(s)
Study population Timing of 
screening
MDT status eNL treatment Type of 
samples
Measures Findings
de Azevedo and 
de Melo (59); 
Brazil
37 lepromatous, 
33 tuberculoid, 18 
“lepra reaction”
ND ND ND Serum Complement unit (K) Reduced complement activity in the reactional group
Angular inclination (1/n)
Wemambu et al. 
(37); United 
Kingdom and 
Malaysia
17 ENL, 6 
lepromatous
ND ND ND Skin Immunoglobulin Perivascular deposits of immunoglobulin and complement
Serum Complement Mycobacterial antigen in some ENL skin lesions
Waters et al. 
(22); United 
Kingdom and 
Malaysia ε
38 lepromatous 
with ENL, 13 
lepromatous
ND ND ND Skin Immunoglobulin and 
complement
Immunoglobulin and complement perivascular in some ENL skin 
lesions
Serum Detection of mycobacterial 
antigen in the ICs
Mycobacterial antigen present in ICs
Gelber et al. 
(69); Taiwan and 
USA
15 LL with ENL, 47 
BT-LL 
3 or more 
specimens 
time-span up to 
4 months in BT 
and LL/ENL and 
up to 6 months to 
LL without ENL
ND ND Serum C1q precipitin activity Association of C1q precipitin activity with ENL
Complement levels C3
Cryoglobulins
Bjorvatn et al. 
(46); Ethiopia 
and Switzerland
13 ENL, 7 LL, 
6 tuberculoid, 
pulmonary TB, 30 
HC
ND All on dapsone 
or clofazimine
ENL patients 
received treatment 
for ENL
Serum ICs with 125I-C1q binding 
assay
ICs increased in ENL and LL but also in tuberculoid leprosy
Complement Increased C3d level in most patients with ENL
Tung et al. (51); 
Ethiopia
22 BL/LL with ENL, 
23TT-LL, 17 SLE
ND 19/23 non-ENL 
on dapsone
Untreated ENL Serum C1q ICs Circulating ICs in 67% of leprosy by C1q test
Raji test ICs Only 7% of this 67% showed ICs by the Raji test
Anthony et al. 
(60); India ε
25 LL with ENL, 10 
LL without ENL
Active ENL 
lesions at the time 
of the biopsy
ND ND Skin Immunoglobulin deposits 
in skin
Immunoglobulin deposits in ENL skin but not in LL
Decreased serum complement in ENL
Serum Complement in sera Elevated levels in LL
Wager et al. 
(44); Finland, 
Brazil, and 
Ethiopia
11 ENL, 112 
leprosy, 61 LL, 7 
tuberculoid, 28 SLE, 
42 RA, 374 HC
ND ND ND Serum ICs with Platelet aggregation 
test (PAT)
Higher PAT titers toward the lepromatous end of the spectrum
Other sero-immunological 
parameters
No significant differences for ENL patients
Izumi et al. (70); 
Japan γ
12 ENL, 49 active 
lepromatous, 
24 inactive 
lepromatous, 
7 borderline, 6 
tuberculoid, 9 HC
ND ND ND Serum C4, C3c, C3 activator C3 activator and C3c concentrations higher in ENL compared with 
active lepromatous
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Measures Findings
Harikrishan et al. 
(71); India ε
20 active LL, 15 ENL 
active and subsided, 
20 HC
ENL: during the 
active and the 
subsided phase
ND ND Serum Complement factor C3 Increased levels of C3 in LL and ENL
Decrease in C3 during the “subsided phase” of reaction
Saha et al. (72); 
India
20 ENL, 15 HC Initial sample first 
visit, subsequent 
on ENL clinical 
remission 
4 weeks later
ND Second sample: 
on antireactional 
treatment
Serum Complement C1q, C3, C4 C3 level decreased during ENL, while increased after remission 
C3d increased during ENL, and remained elevated after clinical 
remission in most patients
No significant difference in C1q or C4 during ENL
Valentijn 
et al. (54); 
Netherlands and 
Surinam
70 leprosy 
throughout the 
whole spectrum, 
11 HC 
ND ND ENL patients 
possibly on 
thalidomide 
treatment?
Serum ICs Elevated C3d significantly associated with ENL
Complement C1q, C3, C4
Mshana et al. 
(73); Ethiopia
26 ENL, 20 BL/LL Skin biopsies of 
ENL less than 
12 h old
ND ND Skin Immunoglobulin deposits
Complement deposits
Mycobacterial antigens
No ICs around blood vessels in ENL lesions IC formation common 
feature in LL
Absence of immunoglobulin or C3 deposits in early ENL
Extracellular antigens not seen
Ridley and 
Ridley (39); 
Malaysia, PNG, 
Ethiopia, and 
UK
20 ENL, 10 non-
reactional leprosy
ND ND ND Skin Immunoglobulins IgG, IgM, 
IgA, IgE
Complement C3, C4, C1q, 
C3d
ENL lesions had disintegration of macrophages and release of 
bacterial antigen combined first with IgM, later with IgG, present 
together with complement components of the classical pathway
ICs were both extracellular and in neutrophils and macrophages
ICs were extravascular
Ramanathan 
et al. (74); India
10 BT, 10 LL, 10 
BT reactional, 30 LL 
reactional
ND All patients on 
dapsone
Sampling before 
antireactional 
treatment
Serum C3 and C4 Increased C3d in both BT reactional (T1R) and LL reactional
ICs
Isolated ICs for IgG, IgA, IgM, 
C3, C4 and antimycobacterial 
antibody
Circulating ICs in all reactional patients No antimycobacterial 
antibody in ICs from LL reactional patients
Saha et al. (75); 
India
20 ENL, 15 HC Before and 
4 weeks after 
starting treatment 
for ENL
ND Second sample: 
on antireactional 
treatment
Serum Quantitative analysis 
of composition of 
PEG precipitates 
(immunoglobulins, 
complement components, 
autoantibodies and acute 
phase proteins) and 
anticomplementary activity of 
PEG precipitates
Anticomplementary activity of PEG precipitates more in the 
lepromatous than in normal sera, independent of the presence of 
ENL
TABLe 2 | Continued
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Measures Findings
Ramanathan 
et al. (48); India
32 LL in reaction, 
10 BT, 10 BT in 
reaction, 10 LL 
uncomplicated, 
15 HC
ND BT and LL 
without reaction 
treatment for at 
least 2 years; all 
patients were on 
dapsone
ND Serum ICs by fluid phase 125I-labeled 
conglutinin binding assay; 
serum C3d
Complement-mediated 
solubilization of immune 
precipitates
Reduced solubilization of in vitro formed immune precipitates by 
the sera of ENL patients
C3d, ICs, and solubilization levels correlated with the clinical course 
of reaction
ICs and C3d decline after clinical subsidence of ENL
Sehgal et al. 
(76); India ε
21 T1R or ENL ND ND ND Serum Complement C3 Lower level of C3 during ENL
Chakrabarty 
et al. (77); India
27 BB-BL-LL: 7 
ENL, 4 T1R
Initial blood 
collected at the 
onset of reaction 
and subsequent 
4 weeks after ENL 
remission
Patients on MDT Second blood 
sample on 
antireactional 
treatment
Serum Solubilization of preformed 
ICs (125I-BSA-anti-BSA 
complexes)
The mean solubilizing capacity of the reaction patients’ sera during 
the reaction was not significantly different from LL without ENL
After clinical remission of the reaction, most patients showed no 
increase in the ICs solubilization
Rao and Rao 
(78); India ε
44 ENL, 39 BL/LL, 
22 post-ENL
ENL: before 
starting treatment 
with anti-
inflammatory 
drugs/steroids
20 BL/LL 
untreated and 
19 BL/LL treated 
with dapsone 
less than a year
Untreated first 
sample and 
second post-ENL 
sample after 
discontinuation 
of antireactional 
treatment
Serum C3 and C4 levels
IgG, IgA, IgM, C3, and C4 
levels in the ICs
ICs by PEG method
C3 and C4 levels were not significantly different in ENL compared 
to BL/LL and post-ENL
C3 and C4 levels in the ICs reduced insignificantly in ENL than BL/
LL and post-ENL
IgG, IgA, and IgM in ICs showed no significant differences from LL 
to ENL and post-ENLPost-ENL: 
ensuring that 
the patient had 
not taken anti-
inflammatory 
drugs/steroids 
for at least 3 or 
7 days
Sehgal et al. 
(79); India
17 ENL Before 
antireactional 
treatment and 
1 week after 
the clinical 
subsidence of 
ENL
On MDT First sample 
untreated and 
second sample on 
prednisolone in 10 
patients
Serum Complement components: 
classic pathway: C1q and C4
Alternative pathway: C3, 
C3d, Factor B
No significant change in classical pathway in ENL reaction C3 
elevated, C3d decreased and increase of Factor B after ENL
Jayapal 1989 
(47); India
37 leprosy: 9 
ENL, 6 bacterial 
endocarditis, 
syphilis, SLE, HC
ND All leprosy 
patients on 
dapsone
ENL patients 
on clofazimine, 
prednisolone, 
antihistamine and 
chloroquine
Serum ICs with PEG method ICs higher in ENL than in LL
TABLe 2 | Continued
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Sehgal et al. 
(81); India
18 T1R, 17 ENL, 
non-reactional 
controls
During and after 
reaction
On MDT ND Serum Complement components: 
classic pathway: C1q and C4
Classic pathway: no significant change in C1q and C4 during ENL
Alternative pathway: increase in C3d during ENL; decrease of C3 
during ENL; reduction of Factor B during ENL; elevation of C3 and 
Factor B after ENL
Alternative pathway: C3, 
C3d, Factor B
Tyagi et al. (52); 
India
20 BL/LL with ENL, 
20 TT/BT, 20 BT 
with reaction, 20 
BL/LL; 15 HC
ND ND ND Serum ICs by PEG precipitation
Mycobacterial ICs in PEG 
precipitates; CH50 assay and 
AH50 assay (complement 
consumption)
PEG ICs from BL/LL and ENL higher IgG and IgM antimycobacterial 
antibodies than TT/BT, BT reactional (T1R) and HC
No significant functional differences between the PEG ICs from 
reactional and non-reactional leprosy
Ramanathan 
et al. (49); 
India ε
26 BL/LL: 11 ENL, 
24 HC
Before initiation 
of treatment 
and 2-monthly 
intervals
Untreated and 
then on MDT
Treated but after 
sampling
Serum ICs by PEG method High levels of ICs in both LL and ENL
C3d Lower levels of complement-induced IC solubilization in ENL
Complement-induced IC 
solubilization
Highest levels of ICs and C3d at the time of ENL
Scollard et al. 
(82); Thailand ε
4 cured leprosy, 
10 non-reactional 
leprosy BT/BL/LL, 8 
ENL patients (5 LL/3 
BL), 3 T1R, 4 HC
ND ND ND Blisters 
induced over 
representative 
skin lesion
ICs ICs in ENL similar to that of active leprosy (either lepromatous or 
tuberculoid)
Higher ICs in blisters than in matching sera
Serum
Rojas et al (50); 
Brazil ε
19 ENL, 10 BL/
LL, 13 family 
contacts; 15 healthy 
non-contacts
ND Both untreated 
and patients 
on MDT for 
1–72 months
ND Serum ICs; anti-PGL-I IgM in IC 
precipitated from sera; 
anti-10-kDa hsp IgG in IC 
precipitated from sera
ENL highest levels of ICs compared with all other groups IgM 
anti-PGL-I and IgG anti-MCP-1 heat shock protein antibodies 
constituents of ICs in ENL
Dupnik et al. 
(58); Brazil δ, ε
11 ENL, 11 T1R, 
19 non-reactional 
leprosy, additional 6 
ENL, 11T1R, 11 HC
ND 3 ENL pre-
treatment, 2 ENL 
on treatment 
and 6 ENL 
post-treatment; 
Leprosy controls 
matched 
for stage of 
treatment
Excluded patients 
who had received 
corticosteroids 
within 7 days 
or thalidomide 
within 28 days of 
enrollment
PBMC Microarray and qPCR for 
transcriptional profile of 
PBMC; IHC for C1q in skin 
lesions
Complement and coagulation pathway common in ENL and T1R
Skin Transcripts uniquely increased in ENL included complement 
receptors C3AR1 and C5AR1
C1q staining higher in both ENL and T1R compared with non-
reactional leprosy
α, also in Table 1; γ, also in Table 3; δ, also in Table 4; ε, also in Table 5.
BB, mid-borderline leprosy; BL, borderline lepromatous leprosy; BT, borderline tuberculoid leprosy; ENL, erythema nodosum leprosum; HC, healthy controls; ICs, immune complexes; LL, lepromatous leprosy polar; ND, not described; 
PEG, polyethylene glycol; PNG, Papua New Guinea; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TB, tuberculosis; TT, tuberculoid leprosy polar; WHO, World Health Organization.
TABLe 2 | Continued
9
P
olycarpou et al.
Im
m
unology of E
rythem
a N
odosum
 Leprosum
Frontiers in Im
m
unology | w
w
w
.frontiersin.org
M
arch 2017 | Volum
e 8 | A
rticle 233
10
Polycarpou et al. Immunology of Erythema Nodosum Leprosum
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 233
whether they are involved in the pathogenesis of ENL or simply 
an epiphenomenon.
wHAT iS THe ROLe OF T-CeLLS iN eNL?
T-lymphocytes are part of the adaptive immune response which 
help to eliminate bacterial, viral, parasitic infections or malignant 
cells. The antigen specificity of the T-cell is based on recognition 
through the T-cell receptor (TCR) of unique antigenic peptides 
presented by major histocompatibility complex (MHC)-molecules 
on APCs: B cells, macrophages, and dendritic cells. There are two 
major T-cell lineages, defined by the presence of two surface co-
receptor molecules, namely, CD4 and CD8. CD4+ cells when they 
are activated produce cytokines as effector T helper cells, whereas 
CD8+ lymphocytes form effector cytotoxic T lymphocytes (CTL). 
Furthermore, activated CD4+ T helper cells can be subdivided 
into Th1, Th2, Th17, and T regulatory (Treg) subsets based on the 
production of signature cytokines (83).
Early studies investigating T-cell biology in the pathophysiol-
ogy of ENL reported that ENL patients had higher T-cell numbers 
in peripheral blood than uncomplicated LL patients, although 
both LL and ENL patients had a significantly lower percentage 
and absolute number of T-cells compared to healthy controls 
(84). In addition, the high numbers of T-cells observed during 
ENL remained high post-ENL treatment compared to the LL 
controls (85).
Patients with ENL had increased CD4+ T cell numbers and a 
simultaneous decrease in CD8+ T cell numbers and an increased 
CD4+/CD8+ ratio in the blood compared to LL controls (86, 87), 
while ENL patients had decreased CD4+/CD8+ ratio after suc-
cessful treatment. This ratio increased in those patients who had 
an ENL recurrence (87). An increased CD4+/CD8+ ratio in ENL 
patients was reported by several subsequent studies (87–92). In 
acute SLE, it has been suggested that the failure of CD8+ T-cell 
activity could lead to increased IgG production and to the 
subsequent formation of ICs (93). However, there are studies in 
ENL reporting a decreased CD4+/CD8+ ratio compared to non-
reactional LL controls (94) or a similar ratio (95, 96).
The first immunohistological studies of T-cell subsets in skin 
lesions included small numbers of ENL patients and assessed the 
percentage and ratio of CD4+ and CD8+ T  cells by comparing 
them to non-ENL lepromatous specimens (89, 91, 97–103). ENL 
skin lesions, like peripheral blood, were characterized by an 
increased CD4+/CD8+ ratio in all but one of these studies (89, 91, 
97–100, 102, 103).
CD4+ T  cells differentiate according to the microenviron-
ment into Th1, Th2 cells, or subsets of Th17 and Treg (104). 
Recent studies have reported the frequency of the newly 
described Th17 and Treg subsets in leprosy (105, 106). Using 
flow cytometry in ENL, the absolute numbers and proportion of 
Tregs were shown to be significantly lower during ENL although 
FoxP3 expression, a marker they used to define Tregs, was higher 
(107). Tregs suppress or downregulate induction and prolifera-
tion of effector T cells (108). Therefore, the observation of lower 
numbers of Tregs in ENL could account for the relatively higher 
proportion of T  cells previously described in multiple ENL 
studies. Two more publications from the same group addressed 
the frequency of Tregs in ENL, defined as CD4+CD25high FoxP3+ 
cells and reported the ratio of Treg/Teffector cells to be low in 
ENL (109, 110). These results should be interpreted with cau-
tion since dichotomizing cells into CD25high and CD25low to 
identify Tregs is highly subjective. There is no consensus on 
the thresholds of CD25 expression to delineate Tregs within 
the CD25high population (111). Variations in FoxP3 expression 
within the CD25high population have been observed even in 
healthy individuals (112).
A recent study that used flow cytometry described a sig-
nificant reduction in percentage of CD4+CD25+FoxP3+ Treg 
cells and mean fluorescence intensity of FoxP3 in PBMC in 
patients with ENL compared to LL controls (113). The observed 
reduction of Tregs in ENL patients could lower the inhibitory 
effects on effector T cells and therefore lead to enhanced Th17 
activity, tipping the balance toward inflammation, as previously 
described in other conditions such as tuberculous pleural effu-
sion (114). Interestingly, an increase of FoxP3 mRNA expression 
by PBMC in ENL patients compared to LL controls has also 
been reported (113). The conflicting results for FoxP3 could be 
due to variation in the flow cytometry gating or the fact that 
FoxP3 mRNA may not be translated to functional FoxP3. A 
previous study measured the expression of Foxp3 by qPCR in 
skin biopsies and PBMC of five patients with ENL and detected 
Foxp3 in all skin and PBMC samples. An upward trend of Foxp3 
in PBMC was described during the first 21 days of thalidomide 
treatment (115). The authors suggested that thalidomide may 
boost Tregs by T-cell costimulation via CD28 and therefore 
augment the IL-2-dependent number and/or function of Tregs 
(115). However, the changes in Foxp3 expression did not reach 
statistical significance, while no IL-2 mRNA was detected in any 
samples (115). Another study addressed FoxP3 expression by 
immunohistochemistry in skin but there was no difference in 
patients with ENL compared to non-reactional leprosy controls 
across the spectrum (116). Recent research suggests that Tregs 
constitute a stable cell lineage whose committed state in a chang-
ing environment is ensured by DNA demethylation of the Foxp3 
locus irrespective of ongoing Foxp3 expression (117). Further 
investigation is needed to better define the role of Tregs in the 
pathogenesis of ENL.
Patients with ENL do not exhibit the phenomenon of “anergy” 
of cell-mediated immune response observed in untreated LL 
patients (118). Patients with ENL had elevated mean prolifera-
tive responses to several mitogens compared to uncomplicated 
LL patients (86, 87), while an enhancement in T-cell-related 
functions during the acute phase of an ENL reaction has also been 
described (94).
The interpretation of the role of T  cell subsets in ENL is 
hampered by small sample sizes and methodological issues. 
63.6% of the 44 studies investigating the role of T-cells in ENL 
(Table 3) are cross-sectional and lack serial sampling before and 
after treatment for ENL. However, it appears that T cell subsets 
do play an important role in ENL because multiple studies report 
an increased CD4+/CD8+ ratio in ENL patients in both skin and 
peripheral blood.
TABLe 3 | Human studies on eNL investigating T-cell biology.
Reference; 
study site(s)
Study population Timing of 
sampling
MDT status eNL treatment status Type of 
samples
Measures Findings
Lim et al. (84); 
USA and Korea 
(mixed ethnic 
background)
7 LL ENL, 20 active LL, 
9 inactive LL, 4 BB, 3 
indeterminate leprosy
ND All patients 
treated with 
Dapsone or 
Clofazimine 
or Rifampicin 
for varying 
durations
5 had received various 
doses of steroids and 
3 were treated with 
steroids at the time of 
the study
Blood T lymphocyte numbers by 
the rosette assay
ENL showed T-lymphocyte numbers significantly higher than 
LL
LL had lower T-lymphocyte numbers than HC
Anders et al. 
(119); Papua 
New Guinea
31 leprosy: 13 BL/LL 
with amyloidosis (11/13 
frequent ENL), 9 BL/LL 
ENL without amyloidosis, 
9 BL/LL with few or no 
ENL episodes
ND Approximately 
half patients on 
clofazimine and 
other half on 
dapsone
2 ENL at testing: 
1 steroids and 1 
stibophen
Blood Lympohocyte 
transformation tests
Patients with a history of frequent ENL had greater cell-
mediated responses to PHA than patients without ENL
Izumi et al. (70); 
Japan β
12 ENL, 49 active 
lepromatous, 24 inactive 
lepromatous, 7 borderline, 
6 tuberculoid, 9 HC
ND ND ND PBMC Percentage and number 
of Tμ (T cells with Fc 
receptor for IgG) and Tγ 
(T cells with Fc receptor 
for IgM)
No significant differences between different clinical groups
Bach et al. (86); 
France (multiple 
ethnic groups)
9 BL/LL with no recent 
history of ENL, 9 BL/LL 
suffered from ENL less 
than 2 months prior to 
the investigation, 13 BT/
TT, HC
ND Some untreated 
and others on 
MDT
Certain ENL on 
antireactional treatment
Blood T cell subsets; Proliferative 
responses to mitogens
Increased %age of helper T cells in ENL
Decreased %age of suppressor T cells in ENL
Elevated proliferative responses to mitogens in ENL
Con A-induced 
suppressive activity
Most ENL decrease of suppressive index, whereas none of 
the LL or TT patients had a diminished suppressive activity
Dubey et al. 
(120); India
41 untreated cases 
of leprosy, 64 TT and 
LL taking antileprosy 
treatment, reactional (8 
ENL and 10T1Rs), 11/41 
follow-up from untreated 
leprosy patients
ND 64 cases on 
antileprosy 
treatment
Untreated cases of 
ENL?
Blood Lymphocytic culture: 
percentage of Blast 
transformation
Blast percentage in ENL slightly higher than T1R
Mshana et al. 
(90); Ethiopia
21 BL/LL, 10 BT, 5 ENL ND All patients 
received MDT 
but unclear 
whether 
sampled prior to 
MDT
No patient on 
thalidomide
Blood Lymphoproliferative 
responses to PPD or PHA
T-cell subsets
Higher responses to PPD or PHA in ENL Decreased number 
of suppressor cells prior to ENL, which increased with clinical 
recovery from ENL
Mshana et al. 
(88); Ethiopia
69 leprosy patients: 26 
ENL, 13 HC
Untreated 
samples
Untreated 
samples
Untreated samples Blood T lymphocyte 
subpopulations; 
lymphoproliferation using 
M. leprae, PHA and PPD
ENL patients had decrease in suppressor cells and an 
increase of CD4+/CD8+ ratio compared to LL ENL had higher 
responses to both PHA and PPD BL/LL patients with or 
without ENL lower proliferative responses to M. leprae than 
BT patients and HC
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sampling
MDT status eNL treatment status Type of 
samples
Measures Findings
Wallach et al. 
(87); France 
(samples from 
multiple ethnic 
groups)
9 recent ENL, 6 
bacteriologically positive 
patients of which 1 ENL 
more than 5 years ago, 9 
treated leprosy patients of 
which 3 had ENL
Described in 
detail each 
patient duration 
of disease
All treatment 
described in 
detail
Some on antireactional 
treatment
Blood T cell subsets; 
Lymphocyte 
transformation tests: 
proliferative responses to 
mitogens
ENL patients have elevated Helper/Suppressor ratio
Mean proliferative responses elevated in ENL
Bach et al. 
(121); France
8 treated lepromatous 
without recent ENL with 
BI < 1 +, 6 lepromatous 
with BI > 2+ (untreated 
or suffering a relapse, 
without recent ENL 
reaction), 12 lepromatous 
who underwent at least 
one ENL episode, 13 
tuberculoid, 41 HC
ND ND ND PBMC T-cell subsets; Proliferative 
response to M. leprae 
and PPD of isolated T-cell 
subsets
ENL decreased CD8+ T cell percentages and increased 
CD4+/CD8+ ratios T-cell subset percentages returned to 
normal either when the bacterial load was reduced by 
treatment or when the ENL reaction resolved ENL episodes 
associated with improvement of T-cell unresponsiveness to 
various antigens or mitogens
Modlin et al. 
(97); USA
15 non-reactional 
leprosy BT/BB/BL/LL, 17 
reactional (6 T1R, 9 ENL, 
2 Lucio’s reaction)
ND Results did not 
differ between 
treated and 
untreated 
subjects
3 ENL had no therapy Skin T lymphocyte subsets The helper/suppressor ratio in ENL was significantly higher 
than in non-reactional lepromatous disease
Modlin et al. 
(98); USA
14 leprosy patients (4 
tuberculoid, 2 borderline in 
T1R, 1 BL, 7 lepromatous 
of which 5 ENL), 8 HC
ND 6 treated 
patients
ND Skin T lymphocyte subsets ENL lesions showed 2:1 predominance of helper cells 
whereas in the lesions without ENL the helper: suppressor 
ratio was 1:1 smaller
Sasiain et al. 
(122); Argentina
16 ENL, 12 HC First blood 
sample 
ND; 9 ENL 
20-30 days 
after stopping 
thalidomide
All patients on 
MDT
Thalidomide in patients 
with ENL
PBMC ConA-induced suppressor 
response
Suppressor T-cell function was reduced during ENL and after 
ENL than HC
Narayanan et al. 
(89); India ε
7 LL ENL, 6 BT T1R, 5BL 
T1R, 18 BT-LL
ND ND ND Skin T cell phenotypes Lesions of ENL showed increase in T cells with a 
predominance of the helper/inducer subset; CD4+/CD8+ ratio 
was higher in ENL and T1R than non-reactional lesions
TABLe 3 | Continued
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Rea et al. (96); 
USA ε
19 ENL, 24 LL non-
reactional with treatment, 
12 LL non-reactional no 
treatment, 18 LL with 
long-term treatment, 4 
LL with Lucio’s, 13 BL, 
13 T1R, 18 Tuberculoid, 
13 Tuberculoid with long-
term treatment
ND Some patients 
on MDT
ENL before receiving 
thalidomide
PBMC T cell subsets Active LL patients have lymphopenia, a proportionate 
reduction in the numbers of each of the three T cell subsets
Insignificant changes in T cell subsets expressed as 
percentages and in the helper: suppressor ratio
Laal et al. (94); 
India ε
15 ENL, 13 LL During active 
ENL and 
1 week to 
4 months 
after stopping 
treatment
On MDT First sample 
before initiation of 
antireactional treatment
Blood Leukocyte migration 
inhibition test
ENL significant inhibition of antigen-induced leukocyte 
migration
Lymphoproliferation Lymphoproliferation enhanced during the acute phase of ENL
Second sample 1 
week to 4 months after 
stopping treatment
Suppressor cell activity; 
T cell subsets
Enhanced antigen-stimulated suppression of mitogen 
responses in ENL
Leukocyte migration inhibition, lymphoproliferation, and 
suppressor cell activity were reduced in post-ENL to the 
unresponsive state seen in stable LL
Lower CD4+/CD8+ ratio in ENL compared to LL
Modlin et al. 
(99); USA
12 ENL and 10 non-
reactional leprosy; 19 ENL 
blood samples
ND ENL biopsies: 
8/12 treated 
with dapsone; 
ENL blood: 
15/19 treated
Some ENL were 
treated
Blood T lymphocyte subsets ENL tissue more cells of the helper-inducer phenotype and 
fewer of the suppressor-cytotoxic phenotype, as compared 
with non-reactional LL
Skin No correlation between tissue and blood helper-suppressor 
ratios
Wallach et al. 
(91); France
ND ND ND ND Blood T cell helper-suppressor 
(HS) ratio
HS ratio higher in ENL lesions and blood than non-ENL 
leprosy controlsSkin
Modlin et al. 
(100); USA
Biopsies: 25 ENL, 23 
tuberculoid, 23 non-
reactional lepromatous; 
ND Some patients 
received 
treatment
Some patients on 
treatment?
Blood Skin: number of T cells, 
T cell subsets; Blood: 
lepromin-induced 
suppression of the Con A 
stimulation
Increases in both CD4+/CD8+ ratio and the number of IL2-
positive cells in ENL
Suppressor activity decreased significantly in ENL
Suppressor activity returned to normal after ENL subsidedBlood: 18 ENL
Skin
Rao and Rao 
(123); India ε
44 ENL, 39 BL/LL, 22 
post-ENL
ENL patients 
before starting 
ENL treatment, 
post-ENL after 
patient had 
not taken anti-
inflammatory/
steroids for 
at least 3 and 
7 days
From 39 non-
reactional cases: 
20 untreated 
and 19 with 
dapsone for less 
than a year
Before starting 
treatment for ENL 
with steroids or anti-
inflammatory drugs, 
post-ENL: ensuring 
that the patient had not 
taken anti-inflammatory 
drugs or steroids for 
at least 3 and 7 days, 
respectively
Blood Sub-population of T cells 
with receptors for Fc 
portion of IgG (Tr) and Fc 
portion of IgM (Tμ)
Tμ/Tr ratio higher in ENL than lepromatous and post-ENL 
patients
TABLe 3 | Continued
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Reference; 
study site(s)
Study population Timing of 
sampling
MDT status eNL treatment status Type of 
samples
Measures Findings
Rao and Rao 
(85); India
77 leprosy: 44 ENL ENL: before 
starting anti-
ENL treatment, 
post-ENL: After 
patient had 
noe taken anti-
inflammatory 
drugs or 
steroids for 
at least 3 and 
7 days
19 patients 
treated with 
dapsone for less 
than 1 year
Before starting 
treatment for ENL with 
anti-inflammatory drugs 
or steroids
Blood Leykocyte migration 
inhibition test (LMIT)
No significant difference in mean migratory index to PHA, 
PPD, sonicate M. leprae
Enumeration of early and 
total T lymphocytes
Whole M. leprae increased response in ENL compared to LL
Lower migratory indices to whole M. leprae in post-ENL than 
LL
%age of early T lymphocytes increased in ENL compared 
to LL
%age of early T lymphocytes remained high in post-ENL 
compared to LL
Cell-mediated immune responses enhanced during ENL and 
return to LL levels once the episode is over
Shen et al. 
(101); USA
10 ENL, 8TT/BT, 10 BL/
LL, 10 T1R
ND ND ND Skin CD3, CD4, CD8 and Ta1 
(memory) positive cells
CD3, CD4 and CD8 showed percentages of positive cells in 
lesions similar between patient groups
PBMC No significant difference in%age of memory T-cells in ENL 
compared to LL
Bottasso et al. 
(124); Argentina
8 LL/ENL, 17 LL, 9 TT, 
11 HC
ND Patients on MDT Patients with ENL were 
not on thalidomide 
treatment but unknown 
whether they were on 
steroids
Blood T-Lymphocytes count 
absolute and relative; 
Lymphocyte functional 
assay: capacity of rosetta 
formation
Active LL showed a decrease in T-lymhocytes
ENL showed a restoration of the levels of T-lymphocytes
Rasheed et al. 
(125); Zambia 
and Pakistan
167 leprosy of which 21 
LL/ENL, 12 BL/T1R, 24 
BT/T1R, 46 endemic HC
ND ND ND Serum 
Lymphocytes
Lymphocytotoxic activity Lymphocytotoxic activity scores were significantly raised in 
patients with reactions
Sasiain et al. 
(126); Argentina
53 leprosy patients TT/
BT/BB/BL/LL and 9 LL/
ENL, 23 HC
ND Received MDT Thalidomide for ENL PBMC Proportion of CD8+ cells Proportion of CD8+ cells was low in LL patients and tended 
to normalize during ENL episodesM. leprae-induced 
suppression of T-cell 
proliferation; Induction of 
IL-2R by culture with M. 
leprae
PHA- and ConA-induced 
proliferation
Bhoopat et al. 
(127); Thailand ε
57 ENL (19 acute/38 
chronic), 61 active LL, 33 
cured leprosy
26 BL/35 
LL newly 
diagnosed and 
untreated 
ND If corticosteroid and/
or thalidomide was 
initiated before or 
during the study, 
precise timing of 
medication was 
recorded with 
respect to the time of 
collection of laboratory 
specimens
Blisters 
induced over a 
representative 
skin lesion
T cell subsets in situ The lesions of chronic ENL showed a decreased number of 
CD8+ cells and increased helper/suppressor ratio compared 
to those in acute ENL and non-reactional leprosy; Systemic 
administration of corticosteroids caused a reduction in the 
CD4+ cell population but did not change CD8+ cell population
TABLe 3 | Continued
(Continued )
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Reference; 
study site(s)
Study population Timing of 
sampling
MDT status eNL treatment status Type of 
samples
Measures Findings
Rea and Modlin 
(102); USA δ
ND ND ND ND Skin T-cell phenotypes: CD4+ 
versus CD8+ cells, γ/δ 
and α/β receptor-bearing 
lymphocytes, T-memory 
and T-naïve cells
ENL lesions predominance of CD4+ cells similar to those in 
tuberculoid (TT/BT?) and T1R
LL patients showed an excess of CD8+cells
Tyagi et al. (53); 
India
4 TT/BT, 5 BL/LL, 4 ENL ND ND ND Blood Effect of isolated 
circulating ICs from BL/
LL or ENL patients to 
lymphocyte transformation 
test on T cells of HC
PEG precipitates isolated from BL/LL or ENL subjects had 
a significant suppressive effect on lymphocyte proliferation 
in HC
Foss et al. (128); 
Brazil δ
28 lepromatous: 11 ENL, 
23 tuberculoid, 19 HC
ND lepromatous 
patients 86% 
treated with 
dapsone
11 ENL at time of 
blood collection no 
immunosuppressive 
drug
Blood T lymphocyte response to 
concanavalin A
Marked reduction on concanavalin A-induced 
lymphoproliferation in patients with ENL
Santos et al. 
(129); Brazil ε
59 LL/BL, 10 ENL, 4 T1R, 
4 post-reactional
ND On MDT No specific treatment 
for reactions before 
blood collection
PBMC Lymphocyte proliferation 
after ConA and M. leprae
T1R showed greater lymphocyte proliferation compared to all 
other groups
de la Barrera 
et al. (130); 
Argentina
7 TT/BT, 20 BL/LL of 
which 3 ENL
ND All patients on 
MDT
ND PBMC T-cell cytotoxic activity 
induced by M. leprae and 
M.tb heat shock protein 
(HSP)
M. leprae hsp65 induced cytotoxic responses only in those 
MB patients undergoing ENL
Vieira et al. 
(131); Brazil δ, ε
95 MB leprosy 
(30LL/65BL) of which 
51 ENL
At leprosy 
diagnosis 
and at onset 
of reactional 
episode
Time of MDT for 
each ENL
Sample before 
thalidomide and 
steroids?
PBMC Lymphocyte 
transformation test (LTT)
Some patients showed lymphoproliferative response during 
ENL
Mahaisavariya 
et al. (103); 
Thailand
17 non-reactional, 8 T1R, 
12 ENL
Biopsy at 
the time of 
diagnosis and 
not the time of 
reaction
ND ND Skin T-lymphocyte subsets %age of CD8 infiltration reduced in ENL compared with non-
reactional lepromatous
The CD4+/CD8+ ratio of ENL statistically significant higher 
than from the non-reactional lepromatous group
Tadesse et al. 
(132); Ethiopia δ
33 leprosy: 14 BT, 11 BT 
T1R, 8 ENL, 11 HC
ND Certain leprosy 
patients were 
treated on MDT
All ENL treated with 
steroids
PBMC Lymphocyte blast 
transformation
Thalidomide treatment did not alter the lymphoproliferative 
response to the mycobacterial antigens during ENL
Mohanty et al. 
(133); India
21 BL/LL ENL, 38 TT/BT/
BL/LL, 29 BT/BL T1R, 
19 HC
ND ND ND PBMC Immune responses 
against Stress 
proteins of M. leprae 
(lymphoproliferation)
ENL: no significant role of stress proteins except a 
heightened lymphoproliferative response to the 28 kDa 
antigen
Serum
TABLe 3 | Continued
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Reference; 
study site(s)
Study population Timing of 
sampling
MDT status eNL treatment status Type of 
samples
Measures Findings
Villahermosa 
et al. (134); 
Philippines δ, ε
22 ENL Before 
thalidomide and 
at study weeks 
3 and 7 during 
thalidomide
MDT continued 
during the study
Samples untreated for 
antireactional drugs 
and during thalidomide 
treatment
Blood Lymphocyte proliferation 
assays (LPA) to 
phytohemagglutinin and 
concanavalin A
Low LPA values pre-thalidomide in both PBMC and whole 
bloodPMBC
Attia et al. (107); 
Egypt
38 leprosy: 6 ENL, 38 HC Untreated 
samples
Untreated 
samples
Untreated samples; 
excluded patients on 
immunosuppressive 
drugs
Blood Frequency of circulating 
Tregs; FoxP3 expression
Significantly lower frequency of Tregs but higher FoxP3 
expression in ENL
Massone et al. 
(116); Brazil ε
20 leprosy: 3 ENL Biopsies at 
the time of 
diagnosis 
10, 12 and 
13 months after 
beginning of 
MDT for LL
Untreated for 
antireactional treatment
Skin Presence, frequency and 
distribution of Tregs
No statistical difference in FoxP3 expression between TT, BT, 
BL, and LL
Significant increase in FoxP3 expression in T1R compared 
to ENL
Rada et al. (135); 
Venezuela ε
? ENL81 LL, 41 BL, 41 
BB, 3% BT
ND ND ND Blood Cell-mediated 
immunological tests to 
mycobacterial proteins
T-lymphocyte proliferative response in reactional and non-
reactional patients was negative
Saini et al. (136); 
India δ
21 MB: 16 ENL, 5 T1R ENL blood 
during reaction 
and at 0.5 and 
1 year after 
the onset of 
reaction
Duration of MDT 
described
ENL patients received 
steroids
PBMC Lymphoproliferation of 
PBMC stimulated with M. 
leprae, recombinant Lsr2 
and 6 synthetic peptides 
spanning the Lsr2
All patients with active ENL showed lymphoproliferation in 
response to peptides A and F
Abdallah et al. 
(109); Egypt δ
43 leprosy: 6 ENL, 40 HC Untreated 
patients
Untreated 
samples
Untreated Blood Circulating Tregs Tregs/Teffs lowest in ENL
Attia et al. (110); 
Egypt δ
43 leprosy: 6 ENL, 40 HC Untreated 
patients
Untreated 
samples
Untreated Blood CD4(+) CD25(high)Foxp3 
(+) regulatory cells
CD4(+)CD25(high)FoxP3(+) Treg levels lowest in ENL
Treg/Teffs lowest in ENL
Hussain et al. 
(92); India
50 leprosy (28 without 
reactions, 11 T1R, 
11 ENL), 50 HC, 50 
pulmonary TB (25 HIV-
TB co-infected and 25 
without HIV infection), 50 
HIV-positive
ND Reactional 
episodes 
following 
antileprosy 
treatment
ND Blood CD3+, CD4+, CD8+ and 
CD4+/CD8+ ratio with flow 
cytometry
CD4+ counts raised during ENL compared to MB patients 
whereas CD8+ counts lower The CD4+/CD8+ ratio doubled 
during reactional episodes of T1R and ENL
Parente et al. 
(137); Brazil
2 ENL, 103 leprosy 
TT/BT/BB/BL/LL 9 
indeterminate, 8 T1R
2 ENL: 12 and 
10 months 
after initiation of 
MDT
2 ENL after 
initiation of MDT
ND Skin Frequency and distribution 
of regulatory T cells
No significant differences in ENL
TABLe 3 | Continued
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wHAT iS THe ROLe OF TNF-α OR OTHeR 
CYTOKiNeS iN eNL?
A role for TNF-α in ENL was first suggested by a Brazilian 
study that included 18 ENL patients at various stages of treat-
ment with steroids or thalidomide (138). Serum TNF-α levels 
varied widely: from undetectable to extremely high levels (138). 
There was no obvious correlation between severity of ENL and 
cytokine levels, while patients who had received treatment had 
lower levels of TNF-α (138). High serum TNF-α levels were 
subsequently shown to decrease significantly during thalido-
mide treatment (139). These findings have been reproduced in 
other populations measuring serum TNF-α levels (128, 131, 
140–147), whereas two studies failed to show increased levels 
of serum TNF-α during ENL (148, 149). The high variability 
in serum TNF-α between studies might be due to patient dif-
ferences. Although genetic differences between different ethnic 
groups cannot be ruled out, it still remains unclear why there is 
such a high variability in the TNF-α levels between individuals 
presenting ENL.
A study of the plasma levels of TNF-α reported increased 
levels during ENL (150) while other studies contradicted this 
finding (115, 134, 151). In fact, Haslett et al., which included 20 
male ENL patients excluding patients with moderate or severe 
ENL–associated neuritis, reported circulating plasma TNF-α 
levels to be lower at time of ENL diagnosis than LL controls 
(115). There was an upward trend in plasma TNF-α levels during 
thalidomide treatment which returned to baseline levels after 
discontinuation of thalidomide (115). This is an indication that 
thalidomide may in fact stimulate paradoxical overproduction of 
TNF-α (115). The inhibition of TNF-α by thalidomide may be 
prominent when macrophage production of this cytokine is high 
but in mild disease plasma levels may not reflect lesional TNF-α 
production (115). Increased TNF-α levels after thalidomide treat-
ment has been described in other conditions such as toxic epider-
mal necrolysis (152) and aphthous ulcers in patients with human 
immunodeficiency virus infection (153). It has been suggested 
that the mechanism of the paradoxical overproduction of TNF-α 
by thalidomide could be due to the propensity of thalidomide to 
costimulate T-cells to produce cytokines including TNF-α (154). 
All the patients in the study of Haslett et al. showed improvement 
in ENL after receiving thalidomide during the first 21  days of 
treatment (115).
Interestingly, the studies that measured the ex vivo PBMC 
production of TNF-α in response to lipopolysaccharide, BCG, 
or M. leprae in patients with ENL as compared to BL/LL patients 
showed consistently greater amounts of TNF-α secretion in 
patients with ENL (150, 155–157).
The successful use of the anti-TNF therapy with infliximab 
and etanercept in three patients with ENL, resulting reduction of 
inflammation and treatment of ENL, is additional evidence of the 
inflammatory role of TNF-α in ENL (158–160).
The results of studies on IFN-γ are more consistent than those 
on TNF-α suggesting an important role for IFN-γ in the patho-
physiology and occurrence of ENL. A clinical trial administered 
recombinant IFN-γ to BL/LL patients as a replacement therapy 
because LL is characterized by anergy to antigens of M. leprae 
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and inability to produce IFN-γ (150). Repeated intradermal 
injection of recombinant IFN-γ induced ENL in 6 out of 10 BL/
LL patients within 7 months compared to an incidence of 15% 
per year in patients who received MDT alone (150). Elevated 
serum IFN-γ was found in patients with ENL who also had 
high TNF-α levels (139). Other studies have demonstrated an 
increase of serum IFN-γ (143, 144, 148) and an increase of 
IFN-γ mRNA in PBMC (161–163) and in skin biopsies (161, 
164) during ENL. There is a study reporting serum IFN-γ to 
be significantly lower in patients at the onset of ENL, which 
increased after thalidomide treatment (142). However, IFN-γ 
has been identified by Ingenuity Pathway Analysis networks as 
the second most significant upstream regulator (after CCL5) 
of the expression changes in microarrays performed in PBMC 
derived from patients with ENL (58).
There are contradictory findings about the role of serum IL-1β 
levels. Most studies have reported that serum IL-1β levels may 
have a prognostic value for developing ENL (144, 148, 165, 166) 
and that there is a statistically significant correlation between 
TNF-α and IL-1β (140). However, studies failed to show any 
association of serum IL-1β or plasma IL-1β with ENL (138, 151). 
IL-1β mRNA in PBMC was upregulated at the onset of ENL (161) 
but not in skin lesions (167).
IL-2 has a key role in the immune system primarily by its direct 
effects on T-cells such as promoting differentiation of different 
T-cell subsets and contributing to the development of T-cell 
immunological memory. IL-2 signals through the IL-2 receptor 
(IL2R), which is essential for the signaling in T-cells. There were 
no differences in the serum IL-2 or IL2 mRNA in skin biopsies 
between ENL and patients with LL (115, 148, 151). However, 
four studies reported an increase in soluble IL-2 receptor (sIL2R) 
levels (115, 131, 165, 168) or IL2Rp55 mRNA in PBMC (161) in 
patients with ENL.
Serum IL-6 (147, 151, 169, 170) and IL-6 mRNA in PBMC and 
skin (161) have been reported to be elevated during ENL. IL-6 tag 
single-nucleotide polymorphisms have been reported to be a risk 
factor for ENL (170) and IL-6 plasma levels were correlated with 
the IL-6 genotypes (170). A study reported increased serum IL-6 
receptor (sIL6R) levels in ENL, which declined significantly after 
the completion of a corticosteroid treatment (143). However, 
other studies did not show associations of IL-6 serum levels with 
ENL (134, 139, 143).
An ex vivo study in PBMC isolated from ENL patients and 
LL controls showed a correlation of raised levels of cytokines 
IL-17A and its isomers as well as other Th17-associated 
cytokines IL-21, IL-22, and IL-23 with ENL (113). However, 
other studies failed to detect an association of ENL with serum 
IL-17 (110, 151, 171).
There are 49 studies measuring cytokines in ENL (Table 4), 
and the majority of these studies show a significant increase of 
the pro-inflammatory cytokines during ENL. TNF-α appears to 
be a regulator of the condition while there is substantial evidence 
supporting a role for IFN-γ as well. There is also evidence that 
other cytokines such as IL-1β and IL-6 or cytokine receptors 
such as sIL2R and sIL6R are also involved. Therefore, inhibitors 
of these molecules may be useful in a clinical setting. It is possible 
that genetic differences could account for differences observed 
between studies but methodological differences are also likely 
factors.
wHAT OTHeR iMMUNe MeCHANiSMS 
ARe iMPLiCATeD iN eNL?
Sixty-four studies on other immunological factors in ENL have 
been performed (Table 5).
innate immunity
Genetic studies have shown associations between several single-
nucleotide polymorphisms (SNP) of innate immunity genes such 
as NOD2 (210), the natural resistance-associated macrophage 
protein (NRAMP1) (211), and TLR1 (212, 213) with ENL.
A recent study from Brazil, which investigated whether DNA 
sensing via TLR9, constitutes a major inflammatory pathway dur-
ing ENL (80) showed that both the skin lesions and peripheral 
leukocytes (B-cells, monocytes, and plasmacytoid dendritic cells) 
of ENL patients express higher TLR9 levels than BL/LL controls 
(80). In addition, the levels of endogenous human and pathogen-
derived TLR9 ligands (human and mycobacterial DNA-histone 
complexes) were also higher in the circulation of ENL patients 
than BL/LL controls (80). Furthermore, stimulation of PBMC 
isolated from ENL patients with TLR9 agonist led to higher levels 
of TNF-α, IL-6, and IL-1β, than those of non-reactional leprosy 
and healthy controls. Usage of a TLR9 synthetic antagonist was 
able to significantly inhibit the secretion of pro-inflammatory 
cytokines after stimulation with M. leprae lysate (80). This is the 
first study to support the potential of TLR signaling inhibitors as 
a therapeutic strategy for ENL (80).
B-Lymphocytes and immunoglobulins
Early studies enumerated B lymphocytes in skin lesions (89) and 
in peripheral blood (76, 78, 94, 123) of patients with ENL, while 
most of these studies did not find any association between B-cells 
and the development of ENL. Other studies looked at the IgM 
PGL-I in sera as a marker for ENL (40, 184, 192, 206), but most 
of these studies did not show an association (50, 82, 149, 187, 194, 
205). Significantly lower serum levels of IgG1 and IgG3 subclasses 
of M. leprae-specific antibodies have been demonstrated in ENL 
patients compared to the BL/LL controls (190). This decrease 
of M. leprae-specific IgG1 and IgG3 antibodies in sera has not 
been related to downregulation of B  cell responses since ENL 
episodes were characterized by an increase of polyclonal IgG1 
antibody synthesis by the B cells, declining after subsidence of the 
reaction (191). The authors suggested that activation of B-cells is 
restricted to IgG1-secreting B cells in the blood of patients with 
lepromatous disease (191), while the lower serum concentrations 
of M. leprae-specific IgG1 and IgG3 (190) could be due to anti-
body deposition in the tissues (191). Interestingly, surface CD64 
(FcγRI), the high-affinity receptor for monomeric IgG1 and IgG3 
is expressed at higher levels on circulating neutrophils derived 
from ENL patients compared to non-reactional leprosy controls 
(25). The higher CD64 neutrophil expression could explain the 
presence of lower serum IgG1 and IgG3 levels in ENL patients 
compared to BL/LL controls.
TABLe 4 | Human studies on eNL investigating cytokines.
Reference; 
study site(s)
Study population Timing of 
sampling
MDT status eNL treatment status Type of samples Measures Findings
Filley et al. (168); 
India ε
7 ENL Before, during and 
after the episode
All patients on 
MDT
ENL treated with 
steroids and/or 
thalidomide
Serum IL2R IL2R increase during ENL
Rea and Modlin 
(102); USA γ
ND ND ND ND Skin IL-2 positive and 
IFN-γ positive mRNA-
bearing lymphocytes
IL2- positive lymphocytes prevalent in ENL and in tuberculoid 
lesions
Cells expressing IFN-γ mRNA in ENL lesions slightly increased 
compared to lepromatous
Sarno et al. (138); 
Brazil
18 ENL, 39 BT/
BL/BB/LL, 4 T1R
ND 16/18 patients on 
various stages of 
MDT/2 untreated
3 ENL on thalidomide 
and 7 ENL on 
prednisone; others 
untreated for reaction
Serum Tumor necrosis factor 
(TNF)-α and IL-1
TNF varied from undetectable to extremely high levels in ENL
No correlation between severity of ENL and cytokine level
Neither TNF nor IL-1 correlate with number or duration of ENL 
episodes
Treated patients with steroids or thalidomide lower TNF
Sehgal et al. 
(172); India
11 ENL, 14 T1R, 
20 leprosy non-
reactional, 10 HC
Before starting 
antireactional 
treatment and when 
clinical signs of 
reaction had abated
On MDT Samples before 
and after starting 
antireactional treatment
Serum IL-2R T1R upgrading group higher IL-2R than ENL
Sullivan et al. 
(173); USA ε
ND ND ND ND Skin IFN-γ and TNF-α 
mRNA 
IFN-γ mRNA in ENL similar to tuberculoid
In LL and ENL lesions about 0.2% of cells expressed TNF-α
Barnes et al. 
(155); USA
12 active ENL, 14 
inactive ENL, 6 
T1R; 11 LL
ND All patients had 
received less 
than 5 years 
chemotherapy
ND PBMC TNF-α ENL: the levels of TNF-α release by PBMC were higher than 
any other leprosy
Thalidomide reduced TNF-α by more than 90%
Parida et al. 
(140); India
12 ENL, 64 
leprosy TT/BT/BB/
BL/LL, 14 T1R
ND Most patients 
before MDT 
treatment
ND Serum TNF and IL-1 Patients undergoing T1R or ENL showed high TNF levels
Significant correlation between TNF and IL-1 in reaction
Sampaio et al. 
(150); Brazil and 
USA
13 LL ENL, 15 LL, 
9 HC
ND All patients were 
receiving MDT 
during the study.
7 ENL patient blood 
samples before 
starting treatment 
with thalidomide and 
6 1-2 weeks after 
thalidomide
Plasma TNF-α ENL patients greater release of TNF-α from monocytes
PBMC High plasma TNF-α in ENL
Monocytes
Bhattacharaya 
et al. (146); India
11 ENL, 14 T1R, 
20 leprosy without 
reactions, 20 HC
Before treatment 
and after clinical 
remission of reaction
on MDT Before antireactional 
treatment with steroids
Serum TNF TNF levels in acute ENL were higher but not significant and 
rose to become significant following treatment and clinical 
remission than HC and MB controls
Foss et al. (128); 
Brazil γ
28 lepromatous: 
11 ENL, 23 
tuberculoid, 19 
HC
ND 86% of 
lepromatous 
patients treated 
with dapsone
Time of blood collection 
no immunosuppressive 
drug
Serum TNF-α TNF was elevated in the serum of ENL patients
(Continued )
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Reference; 
study site(s)
Study population Timing of 
sampling
MDT status eNL treatment status Type of samples Measures Findings
Sampaio et al. 
(139); Brazil ε
49 BL/LL: 24 
developed ENL
At the time of 
developing ENL, 
during thalidomide 
treatment, or 
after thalidomide 
treatment was 
discontinued; 
collected at 
1-3, 6-7, and/
or 13-21 days of 
thalidomide and 
1-2 months after 
thalidomide
MDT was 
continued through 
the study
Thalidomide treatment 
for ENL
Sera TNF-α, IL-6, IFN-γ ENL highest TNF-α levels, which decreased significantly 
during thalidomide treatment Serum IFN-γ elevated in patients 
with high TNF-α levels
Santos et al. 
(156); Brazil
14 ENL (4 BL/10 
LL), 12 BL/LL, 
11 HC, 4 ENL 
post-reactions
ND Half untreated 
and the other half 
treated with MDT
ENL patients 
were treated with 
thalidomide?
PBMC TNF-α: spontaneous 
and M. leprae 
stimulated
ENL patients showed significantly greater release of TNF-α 
both spontaneously and induced by M. leprae-induced 
release in ENL patients
Vieira et al. (131); 
Brazil γ, ε
95 MB (30 LL/65 
BL) of which 51 
ENL
At leprosy diagnosis 
and at onset of 
reactional episode
Time of MDT for 
each ENL 
Sample before 
thalidomide and 
steroids?
Serum TNF-α, soluble IL-2R TNF-α increased in 70.6% of ENL patients
Memon et al. 
(141); Pakistan
12 ENL, 27 
leprosy (TT/BT/BL/
LL), 14 household 
contacts and 22 
endemic HC with 
no known leprosy 
contact
At the onset of ENL 
before initiation 
of treatment for 
reaction and after 
the reaction had 
subsided
10/12 ENL 
received previous 
MDT
Samples before 
antireactional treatment
Serum TNF-α TNF levels higher during acute phase of ENL and declined 
after clinical remission of the reaction
Moubasher et al. 
(148); Egypt
35 reactional (19 
ENL/16 T1R), 55 
leprosy, 20 HC
ND Untreated ENL? Untreated ENL? Serum IFN-γ,IL-2, IL-2R, 
IL-10, TNF-α, IL-1β
Both T1R and ENL showed significantly higher serum IFN-γ, 
IL-2R and IL-1β compared to non-reactional leprosy ENL 
showed increased levels of IL-10 compared to T1R
Moubasher et al. 
(165); Egypt
35 reactional (19 
ENL), 36 non-
reactional, 20 HC
PB patients 
assessed after 6 
and 12 months of 
MDT/MB assessed 
after 12 months of 
MDT; Before and at 
the end of treatment 
with MDT
Before and after 
treatment with 
MDT
Corticosteroids were 
given to control the 
reactions
Serum IL-2R, IL-10, IL-1β IL-1β levels may have a prognostic marker for the 
development of reactions
Partida-Sanchez 
et al. (142); 
Mexico ε
9 ENL, 10 non-
ENL, 10 HC
Beginning of 
reaction and after 
1 and 2 months of 
thalidomide
All patients on 
MDT
Untreated samples and 
after 1 and 2 months of 
thalidomide
Serum TNF-α, IFN-γ TNF-α was significantly higher in ENL compared to non-ENL
TNF levels decreased after ENL treatment
IFN-γ significantly lower in patients at the onset of ENL and 
increased after thalidomide
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sampling
MDT status eNL treatment status Type of samples Measures Findings
Sampaio et al. 
(147); Brazil
18 MB with ENL 
(5BL/13LL)
Biopsies at 
diagnosis, at onset 
of reaction, and after 
3 and/or 7 days 
of pentoxifylline; 
Serum: day 0 
(during ENL), 
3-7, 10-14, 30 
and 60 days after 
pentoxifylline
7 patients with 
ENL newly 
diagnosed; others 
on MDT
Pentoxyfylline, 2 ENL 
patients on thalidomide
PBMC Serum TNF-α, IL-6, 
IL-10
Elevated TNF-α in the sera of ENL
Serum TNF-α, IL-6, IL-10 
release by PBMC 
following M. leprae 
stimulation or LPS 
stimulation
Treatment with pentoxifylline reduced TNF-α
Serum levels of IL-6 increased during ENL
High TNF-α mRNA expression in lesions during ENL which 
decreased following treatment with pentoxifylline
Skin TNF-α, IL-6, IL-10 
gene expression at 
skin
IL-6 mRNA reduced by up to 50-fold after treatment
Moraes et al. 
(161); Brazil
53 leprosy: 20 
ENL, 11 T1R
At the time of 
leprosy diagnosis 
(unreactional) and 
at the onset of first 
reactional episode 
(reactional)
MDT was 
continued through 
the study
No anti-inflammatory 
drugs at the time of 
sample collection
PBMC IL-1β, IL-6, IL-8, 
GM-CSF, IFN-γ,IL-
2Rp55, perforin, 
TNFβ, TNF-α mRNA 
in PBMC;  
IL-4, IL-6, IL-8, IL10, 
IL-12, IFNγ, TNFα 
mRNA in skin
In 7 ENL higher incidence of IFN-γ, perforin, GM-CSF, IL2R 
mRNA in blood
Upregulation of IL-1β, IL-6, GM-CSF, IL-2R, IFN-γ mRNA in 
blood at onset of ENL at 3 ENL follow-up
 
3 patients sequential 
sampling and after 
thalidomide
 
Skin
 
Skin lesions ENL: IFNγ and IL-4 differentially expressed
Oliveira et al. 
(33);Brazil α
10 BL/LL: 6 ENL, 
10 HC
ND On MDT ND Blood, 
P.B.Neutrophils
TNF-α, IL-8 Stimulated neutrophils secrete IL-8 and TNFα
Increased TNF-α secretion from neutrophils after LPS 
stimulation
Thalidomide inhibited TNF-α by neutrophils
Goulart et al. 
(174); Brazil
19 leprosy: 5 
ENL/3 T1R, 9 HC
Untreated samples Untreated 
samples
Untreated samples PBMC TGF-β1 in 
supernatants from 
adherent PBMC after 
stimulation with PGL-
1, LPS or serum-free 
RPMI
Adherent PBMC from ENL secrete higher TGF-β1
Moraes et al. 
(164); Brazil
13 MB: 10 ENL, 
3 T1R
Before and during 
pentoxyfilline or 
thalidomide
All patients on 
MDT
Before and during 
pentoxyfilline or 
thalidomide
Skin mRNA expression: 
IFN-γ, IL-6, IL-10, 
IL-12 p40, TNF-α, 
IL-4
Expression of IFN-γ, IL-6, IL-10, IL-12 p40, TNF-α at the onset 
of reactional episodes (T1R and ENL) but IL-4 rarely detected 
Follow-up: TNF-α mRNA and IFN-γ, IL-6 and IL12p40 mRNA 
decreased after thalidomide or pentoxyfylline
Nath et al. (162); 
India
36 ENL, 105 TT/
BL/LL 7T1R, 9 HC
ND All patients on 
MDT
ENL patients before 
antireactional treatment
PMBC IFN-γ, IL-4, IL-10, 
IL-12
ENL: 58% demonstrated a polarized Th1 pattern with only 
30% expressing both cytokines
Nath et al. (163); 
India
1 BL/7 LL ENL, 2 
BL/6 LL8 stable
ND Most patients on 
MDT
ENL patients prior to 
antireactional therapy
PBMC Real-time PCR 
forIFN-γ, IL4, IL10, 
p40 IL12
IFN-γ detectable in all and IL12p40 in half of ENL IL12p40 
mRNA higher in ENL compared to stable lepromatous
Sampaio et al. 
(157); Brazil
15 leprosy: 10 
ENL
ND On MDT ND PBMC, 
monocytes, 
monocytes/T-
lymphocytes 
cocultures
TNF-α after 
stimulation with M. 
leprae
Isolated monocytes from ENL released significantly more 
TNF-α in response to M. leprae than monocytes from 
non-reactional
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study site(s)
Study population Timing of 
sampling
MDT status eNL treatment status Type of samples Measures Findings
Tadesse et al. 
(132); Ethiopia γ
14 BT, 11 BT T1R, 
8 ENL, 11 HC
ND ND All ENL treated with 
steroids
PBMC TNF-α in culture 
supernatants
Thalidomide resulted in suppression of TNF-α production
Haslett et al. 
(115); Nepal
20 ENL, 20 LL 
with no history 
of ENL within the 
preceding 30 days
Blood samples: 
days 0, 3, 7, 14, and 
28 of thalidomide; 
ELISPOT: days 0, 7, 
21, and 28
All (except 1 
patient) on MDT
Excluded patients 
who had received 
immunomodulating 
therapy within the 
preceding month
Plasma
T-cells
Skin
Plasma levels of 
IFN-γ, TNF-α, soluble 
IL2R, IL-12, IL-12 
p40 and IL-12 p70
ELISPOT for IFN-γ; 
Flow cytometry for 
cytokine production 
by T cells
Circulating TNF-α levels lower at ENL diagnosis than controls
Upward trend during thalidomide ENL baseline plasma levels 
of IL-12 lower than controlFlow cytometry: 
days 0, 7, and 21; 
qRT-PCR: PBMCs 
days 0, 7, 21 qPCR: IL-2 genes Baseline levels of sIL2R higher in ENL than controls
Thalidomide increased T cell subsets expressing both IL-2 
and IFN-γ
Villahermosa 
et al. (134); 
Philippines γ, ε
22 ENL Before thalidomide 
and at study weeks 
3 and 7 during 
thalidomide
MDT was 
continued 
Samples untreated for 
antireactional drugs and 
during thalidomide
Plasma TNF-α, IL-6 TNF-α levels not detected
IL-6 unchanged or reduced following thalidomide from week 
0 to week 3
IL-6 undetectable at weeks 3 and 7
Belgaumkar et al. 
(169); India
71 BT/BB/BL, 
11 pure neuritic, 
6 T1R, 1 ENL, 
30 HC
Untreated samples Untreated 
samples
Patients on antileprosy 
treatment or steroids 
were excluded
Serum IL-6, IFN-γ The one patient with ENL had higher levels of IL-6 and IFN-γ 
in comparison to the BL/LL patients without reactions
Iyer et al. (143); 
Indonesia ε
131 TT/BT/BB/
BL/LL, 44 ENL, 5 
T1R, 112 HC
ND Patients on MDT Prednisolone to treat 
reactions
Serum IL-6, IFN-γ, TNF-α, 
IL-6R, IL-10, IL-4, 
sCD27
IFN-γ and IL-6R increased in ENL compared to non-ENL
Completion of corticosteroid treatment: IFN-γ, TNF-α, sIL6R 
declined
Stefani et al. 
(151); Brazil
10 ENL, 10 T1R, 
29 non-reactional 
controls
Newly detected 
untreated patients
Untreated 
samples
Untreated samples Plasma TNF-α, IFN-γ, 
IL12p70, IL-2, IL-17, 
IL-1β, IL-6, IL-15, 
IL-5, IL-8, MIP-α, 
MIP-β, RANTES, 
MCPI, CCL11/
eotaxin, CXCL10, 
IL-4, IL-10, IL13, 
IL-1Rα, IL-7, IL-9, 
G-CSF, PDGF BB, 
bFGF, VEGF
IL-6, IL-7 and PDGF BB elevated in ENL
Motta et al. (175); 
Brazil
44 leprosy of 
which 15 ENL, 
10 HC
Baseline and 7 days 
after therapy for oral 
infection
ND ND Serum IL-1, TNF-α, IL-6, 
IFN-γ,IL-10
No specific finding for ENL
Teles et al. (176); 
Brazil ε
32 leprosy: 10 
ENL, 8 T1R
4 ENL patients 
before and during 
reaction
All patients on 
MDT
ND Skin TNF-α gene 
expression and levels 
in supernatants
PBMC stimulated with M. leprae: upregulation of gene 
expression of TNF-α and increase of TNF-α in supernatants 
after 1, 3, and 6 h
PBMC
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Jadhav et al. 
(149); India ε
303 MB: 5 ENL Serum samples 
at the time of 
recruitment
Newly registered: 
no MDT
Untreated Serum TNF-α No significant outcome for ENL
Madan et al. 
(144); India
61 leprosy: 4 ENL 
and 2 ENL during 
study
Untreated samples, 
during reactional 
episodes and after 
completion of 
treatment
Untreated 
patients
Patients on steroids 
were excluded
Serum TNF-α, IFN-γ, IL-1β, 
IL-10
All cytokines were raised in reactional (both T1R and ENL) 
compared to non-reactional IFN-γ, IL-1β and IL-10 were 
higher in ENL but only IL-10 was statistically significant 
compared to T1R
Levels of all cytokines decreased after MDT
Rodrigues et al. 
(145); Brazil
18 LL with ENL 
during treatment; 
13 non-reactional 
BT, 37 non-
reactional BL/LL, 
25 BL with T1R 
during treatment; 
21 HC
Beginning of 
leprosy treatment, 
at diagnosis of 
reactional episode 
and at 3-5 years 
post-treatment
Samples before 
and during MDT
Untreated samples and 
after treatment with 
prednisolone
Serum TNF-α TNF-α higher during ENL than prior to the reaction
Chaitanya et al. 
(177); India
21 ENL, 80 T1R, 
80 leprosy without 
reaction, 94 
non-leprosy 
Untreated samples Untreated 
samples
Untreated samples Serum IL-17F IL-17F elevated during T1R but no significant difference in ENL
Lockwood et al. 
(178); India ε
303 MB leprosy: 
13 ENL 
Skin biopsies at 
enrollment
Before MDT Before antireactional 
treatment
Skin TNF-α and TGF-β 
immunostaining
TNF-α: similar levels ENL and non-ENL TGF-β: no difference in 
ENL and non-ENL
Martiniuk et al. 
(179); Nepal and 
USA ε
7 ENL Pre- and post- 
treatment with 
thalidomide
ND Pre- and post- 
treatment with 
thalidomide
Skin biopsies RT-PCR for hIL-17A, 
hIL-17B, hIL-17C, 
hIL-17D, hIL-17E, 
hIL17F
IL17A, was consistently seen before and after thalidomide
Reduction in IL17B, IL17E and increase of IL17C following 
thalidomide
Sousa et al. 
(170); Brazil
33 ENL, 54 T1R, 
16 reaction-free 
leprosy
ND 63.8% presented 
ENL during MDT
ND Plasma IL-6 Higher IL-6 in ENL and T1R compared to non-reactional
Abdallah et al. 
(171); Egypt
43 leprosy: 6 ENL, 
43 HC
Untreated samples Untreated 
samples
Untreated samples Serum IL-17, IL-4 Overproduction of IL-4 in LL patients
Saini et al. (136); 
India γ
21 MB: 16 ENL, 
5 T1R
ENL blood during 
reaction and at 0.5 
and 1 year after the 
onset of reaction
Duration of MDT 
described
ENL patients received 
steroids
PBMC PBMC stimulated 
with M. leprae, 
recombinant Lsr2 and 
6 synthetic peptides 
spanning the Lsr2 
sequence: IFN-γ
During ENL stimulated PBMC showed IFN-γ release
Abdallah et al. 
(109); Egypt γ
43 leprosy: 6 ENL, 
40 HC
Untreated patients Untreated 
samples
Untreated samples Serum IL-1β, IL-4, IL12p70, 
IFN-γ
IL-4 highest among LL compared to ENL
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Attia et al. (110); 
Egypt γ
43 leprosy: 6 ENL, 
40 HC
Untreated samples Untreated 
samples
Untreated samples Serum IL-17, IL-22, IL-10, 
TGF-β
No statistically significant difference between groups
Berrington et al. 
(167); Nepal
85 leprosy: 9 
ENL, 35 BL/LL 
non-reactional
ND ND ND Skin RT-PCR for CCL1, 
CCL2, CCL17, 
CCL18, IFNA1, 
IFNA8, IFNB1, IFNG, 
IL10, IL12a, IL12b, 
IL13, IL17a, IL18, 
IL1b, IL1ra, IL21, 
IL22, IL23, IL27, IL29, 
IL4, IL6, TNF
CCL18, IL12b and CD14 elevated in lesions of ENL but failed 
to reach significance when adjusted for multiple comparisons
Sallam et al. 
(166); Egypt
43 leprosy: 6 ENL, 
43 HC
Untreated samples Untreated 
samples
Untreated samples, 
excluded patients on 
corticosteroids
Serum IL-1β, IL-12 Higher IL-1β in ENL compared to non- reactional
No significant difference for IL-12
Dupnik et al. (58); 
Brazil β, ε
11 ENL, 11 
T1R, 19 leprosy 
without reactions 
for microarray; 6 
ENL, 11 T1R, 11 
non-reactional 
for qPCR; 3 ENL 
for ICH
ND 3/11 ENL pre-
treatment, 2/11 
ENL on treatment 
and 6/11 post-
treatment; leprosy 
controls matched 
for length of 
treatment
Excluded patients on 
steroids within 7 days 
and thalidomide within 
28 days of enrollment
PBMC Microarrays followed 
by qPCR
Cytokine-cytokine receptor interaction has been in the top 
3 KEGG pathways in ENL CCL5 followed by IFN-γ was the 
most significant upstream regulator of the expression changes 
in the array
Saini et al. (113); 
India γ
66 leprosy: 15 
T1R, 15 ENL, 36 
stable leprosy 
without previous 
history or clinical 
evidence of 
reactions
Newly diagnosed 
leprosy patients 
prior to institution of 
antireaction therapy
Untreated 
samples
Untreated samples PBMC Antigen (MLSA) 
stimulated and 
unstimulated PBMC: 
gene expression with 
PCR array for 84 
genes
ELISA for cytokines 
IL-17A/F, IL-21, 
IL-22, IL-23A, IL-6, 
IL-1β, IFN-γ, TGF-β in 
supernatants
IL-23A mRNA expression increased in ENL
IL-23R expression increased in ENL
High expression of CCL20 and CCL22 in ENL
ENL significant fold increase in IFN-γ
Culture supernatants: 
Higher IL-17A/F in ENL patients compared to LL
IL23A increased compared to LL
IL-1β increased in ENL
Dias et al. (80); 
Brazil ε
30 ENL, 24 BL/LL, 
31 HC
Upon diagnosis of 
reaction
BL/LL before MDT 
but most ENL 
patients on MDT
Before treatment with 
thalidomide or steroids
PBMC TNF, IL-6 and IL-1β 
in response to TLR9 
agonist
Higher production of TNF-α, IL-6, IL-1β in response to TLR9 
agonist
TLR9 antagonist inhibited the secretion of cytokines in 
response to M. leprae lysate
α, also in Table 1; β, also in Table 2; γ, also in Table 3; ε, also in Table 5.
BB, mid-borderline leprosy; BL, borderline lepromatous leprosy; BT, borderline tuberculoid leprosy; ENL, erythema nodosum leprosum; HC, healthy controls; ICs, immune complexes; LL, lepromatous leprosy polar; ND, not described; 
P.B.neutrophils, peripheral blood neutrophils; SLE, systemic lupus erythematosus; TB, tuberculosis; TT, tuberculoid leprosy polar.
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TABLe 5 | Human studies on eNL investigating other immunological factors.
Reference; 
study site(s)
Study population Timing of 
sampling
MDT status eNL treatment 
status
Type of samples Measures Findings
Waters et al. (22); 
United Kingdom 
and Malaysia β
38 lepromatous ENL ND ND ND Serum Immunoglobulins No differences in immunoglobulin levels
Reichlin et al. 
(180); Malaysia
13 LL of which 7 ENL ND ND ND Blood Euglobulin IgG Levels of euglobulin IgG higher in the ENL-positive patients than 
in ENL-negative patientsSerum IgG
Anthony et al. 
(60); India β
25 LL ENL, 10 LL 
without ENL
Active ENL 
lesions?
ND ND Serum Immunoglobulins High levels of immunoglobulins in both LL and ENL
Harikrishan et al. 
(71); India β
20 active LL; 15 ENL 
during active and 
subsided phase; 20 HC
ENL: during 
the active and 
subsided phase
ND ND Plasma Immunoglobulins IgG, 
IgM, IgA
Serum levels of IgG and IgM during subsidence of ENL were 
significantly lower compared to that during the active phase of 
ENL
Humphres et al. 
(181); USA
14 LL ENL, 28 BL/LL, 
21 HC
Multiple Serial 
sampling 
10/19 LL 
patients 
untreated, 9/19 
LL patients 
Dapsone
Corticosteroids day 
prior to initial assay 
for NK activity and 
was continued 
through treatment
PBMC Natural killer cell 
activity
Natural killer cell activity significantly depressed in ENL
Rea and Yoshida 
(182); USA
108 leprosy (4 
untreated ENL, 14 
dapsone-treated active 
ENL, 10 dapsone-
treated inactive ENL), 
25 HC
ND 54 untreated 
patients 
and others 
dapsone-treated
Untreated Blood Macrophage 
migration inhibition 
activity
Positive serum inhibitory activity strongly associated with 
reactional states (ENL or T1R or Lucio’s reaction) in both treated 
and untreated patients
Miller et al. (183); 
USA
9 leprosy: 3 T1Rs and 
2 ENL
Serial sampling 
from date of 
initiation of therapy 
until the first year 
of treatment
On MDT Reactional 
episodes were 
treated with 
corticosteroids and 
1 ENL received 
thalidomide
Plasma Antibodies to 
Mycobacterial 
Arabinomannan
High levels of antibody to Arabinomannan in 2 ENL patients
Narayanan et al. 
(89); India γ
35 leprosy patients: 7 
LL with ENL, 6 BT, 6 
BT with T1R, 4 BL, 5BL 
with T1R, 8 LL
ND ND ND Skin B cells No increase of B cells in any of the lesions
Rea et al. (96); 
USA γ
19 ENL, 67 BL/LL 4 LL 
with Lucio’s, 13 T1R, 
18 Tuberculoid, 13 
Tuberculoid long-term 
treatment
ND Some patients 
on MDT
ENL before 
receiving 
thalidomide
PBMC B-cells B-cell percentage in the PBMC of ENL similar LL
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Schwerer et al. 
(184); USA
121 leprosy (including 
ENL), 28 contacts, 
15 HC
ND ND ND Serum Anti-PGL I IgM levels Serum anti-PGL I IgM levels lower in ENL compared to patients 
with comparable BI
Andreoli et al. 
(40); India
12 ENL ND All patients 
on MDT with 
specified 
duration
Treated with 
prednisone and/or 
thalidomide
Serum Circulatory IgM 
antibody levels to the 
PGL I; IgM, IgG, IgA 
antibody levels to 
M. leprae antigenic 
preparation
During ENL: decrease of circulatory IgM antibody levels to PGL 
I but no significant change to IgG, IgM or IgA antibody levels to 
the soluble antigens from M. leprae
Laal et al. (94); 
India γ
15 ENL, 13 LL During active ENL 
and 1 week to 
4 months after 
stopping treatment
Treatment with 
combination 
antileprosy 
drugs was 
continued 
throughout
First sample 
before initiation 
of antireactional 
treatment; second 
sample 1 week 
to 4 months after 
treatment
PBMC B cells B-cell percentages in PBMC of ENL patients were similar to 
those of uncomplicated LL
Blavy et al. (185); 
Senegal
34 ENL and 50 leprosy 
patients
ND ND ND Lymphocytes HLA phenotyping Not significant findings of any HLA phenotype regarding ENL
Levis et al. (186); 
USA
ND ND ND ND Serum IgM and IgG 
antibodies to PGL-I
ENL lower anti-PGL-I IgM than non-ENL of comparable BI
Rao and Rao 
(123); India γ
44 ENL, 39 LL, 22 
post-ENL
ENL cases before 
starting treatment 
for ENL, post-ENL 
after the patient 
had not taken 
anti-inflammatory 
drugs or steroids 
for at least 3 and 
7 days
From 39 
non-reactional: 
20 untreated 
and 19 with 
dapsone for less 
than a year
ENL before starting 
ENL treatment, 
post-ENL after 
the patient had 
not taken anti-
inflammatory drugs 
or steroids for at 
least 3 and 7 days
Blood B lymphocytes in 
peripheral blood
B cells: no difference between groups
Sehgal et al. (76); 
India β
21 patients with leprosy 
reactions either T1R 
or ENL
ND ND ND B-cells Percentage 
and absolute 
count of B-cells; 
Immunoglobulins IgG, 
IgA, IgM
During ENL a significant increase in the percentage and 
absolute count of B-lymphocytes Significantly elevated serum 
immunoglobulin values after subsidence of ENL
Serum
Levis et al. (187); 
USA
40 ENL, 63 leprosy 
without ENL, HC
ND ND ND Serum IgM antibody to 
PGL-I; IgM and IgG 
Abs to M.tb and M. 
leprae LAM
No correlation between IgM or IgG Ab to LAM and bacillary index
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Rao and Rao 
(85); India
44 ENL, 39 
lepromatous, 22 
post-ENL
ENL blood before 
starting ENL 
treatment, post-
ENL after patient 
does not take any 
anti-inflammatory 
drugs or steroids 
for the last 3 or 
7 days
20 patients no 
previous MDT 
and 19 treated 
with dapsone
Before starting 
treatment with anti-
inflammatory drugs 
or steroids
Blood Leukocyte migration 
inhibition test
Lower migratory indices to whole M. leprae during ENL
Rao and Rao 
(78); India β
44 ENL, 39 BL/LL, 22 
post-ENL
ENL before 
starting anti-ENL 
treatment, post-
ENL ensuring that 
the patient had 
not taken anti-
inflammatory drugs 
or steroids for at 
least 3 or 7 days
20 BL/LL 
untreated and 
19 BL/LL treated 
with dapsone
Before starting 
treatment with 
steroids or anti-
inflammatory drugs
Serum IgG, IgA, IgM IgG and IgM decreased in ENL than lepromatous and post-ENL
Serum IgA elevated in ENL than lepromatous group and further 
increase post-ENL
Filley et al. (168); 
India δ
7 ENL Before, during and 
after the episode
All patients on 
MDT
ENL was treated 
with steroids and/
or thalidomide
Serum %GO During ENL%GO transiently raised, and this rise parallels an 
increase in circulating IL2R
Bhoopat et al. 
(127); Thailand γ
57 ENL (19 acute/38 
chronic), 61 active LL, 
33 control patients 
whose leprosy had 
been cured
26 BL and 35 LL 
newly diagnosed 
and untreated
ND When treatment 
with corticosteroids 
and/or thalidomide 
was initiated 
precise timing 
was recorded with 
respect to the time 
of collection of 
specimens
Blisters 
induced over a 
representative 
skin lesion
IgM antibody to PGL-I 
and Tac peptide
IgM antibody to PGL-I and Tac peptide levels were elevated in 
chronic ENL lesions
Corticosteroids reduced IgM antibody to PGL-I but did not 
change the levels of Tac peptide
Ramanathan 
et al. (49); India β
26 BL/LL of which 11 
ENL, 24 HC
Blood was taken 
before initiation 
of treatment and 
then to 2-month 
intervals up to 
20 months
Untreated and 
then on MDT 
samples every 
2 months
Treated but after 
blood sampling
Serum IgG, IgA and IgM ENL no significant relation with immunoglobulin levels
Sullivan et al. 
(173); USA δ
ND ND ND ND Skin ICAM-1, ICAM-1 
ligand LFA-1
Prominent keratinocyte ICAM-1 expression
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Scollard et al. 
(82); Thailand β
4 cured leprosy, 10 
leprosy (5BT, 3BL, 
2LL), 8 ENL patients 
(5LL and 3BL), 3 T1R, 
4 HC
ND ND ND Blisters 
induced over 
representative 
skin lesion
Immunoglobulins (IgG, 
IgA, IgM) to whole M. 
leprae and to PGL-I
No statistically significant difference regarding immunoglobulins
Sera
Sehgal et al. 
(188); India
25 leprosy with 
reactions (of which 
11 ENL), 20 leprosy 
without reactions, 10 
HC
ND On MDT Reactional patients 
on prednisolone
Lymphocytes Lymphocyte 
adenosine deaminase 
activity (L-ADA)
The patients with leprosy reactions (both ENL and T1Rs) had 
higher enzyme l-ADA than controls (the enzyme has a role in 
activation, differentiation and proliferation of lymphocytes)
Sampaio et al. 
(139); Brazil δ
49 BL/LL of which 24 
ENL
ENL at the time of 
developing ENL, 
during thalidomide 
treatment, or 
after thalidomide 
treatment
MDT was 
continued 
through the 
study
Certain ENL 
during thalidomide 
treatment
Skin biopsies MCH II and ICAM-1 in 
histology
MHC II and ICAM-1 on epidermal keratinocytes in ENL 
downregulated with thalidomide
Santos et al. 
(129); Brazil γ
10 ENL, 59 LL/BL, 4 
T1R, 4 post-reactional
ND On MDT No antireactional 
treatment before 
blood collection
PBMC, 
Monocytes
Monocyte activation 
by procoagulant 
activity, HLA-DR
No significant difference in monocyte activation between the 
different groups No significant differences in HLA-DR between 
groups
Singh et al. (189); 
India
44 active ENL, 48 prior 
history of ENL, 125 
stable lepromatous, 40 
HC not endemic
ND ND Untreated samples Serum Antibodies against 
B cell epitopes of M. 
leprae recombinant 
protein LSR
Antibodies against a specific distinct peptide region only in 
patients undergoing ENL
Kifayet and 
Hussain (190); 
Pakistan
67 BL/LL acute ENL, 
83 non-reactional BL/
LL, 77 endemic HC
ND Most on MDT 
but 83 non-
reactional less 
than 2 weeks of 
MDT
ND Plasma M. leprae-specific IgG 
subclasses
Lower concentrations of all IgG subclasses during ENL but lower 
IgG1 and IgG3 during ENL before treatment
Kifayet et al. 
(191); Pakistan
13 ENL acute and 
post-remission of 
reaction, 16 non-
reactional stable LL, 32 
endemic HC
During acute ENL 
(n = 13) and after 
the reaction has 
subsided
ND ND Plasma IgG subclasses 
M. leprae-specific 
antibodies;  
Detection and 
enumeration of 
antibody-secreting 
B cells by ELISPOT
Polyclonal IgG1 elevated in acute ENL compared LL controls and 
decreased when ENL subsided
IgG2 antibodies lower during acute ENL and increased after 
reaction has subsided
Discrepancy in serum concentrations and B cell frequency
B-cells
Vieira et al. (131); 
Brazil γ, δ
95 MB leprosy (30 LL 
and 65 BL) of which 
51 ENL
At leprosy 
diagnosis and at 
onset of reactional 
episode
Time of MDT 
for each ENL 
patients in study
Sample before 
thalidomide and 
steroids?
Serum Circulating anti-neural 
and antimycobacterial 
antibodies
Detection of anti-neural (anti-ceramide and anti-
galactocerebroside) antibodies in ENL sera
No difference between reactional and non-reactional 
lepromatous patients regarding IgM antibodies
Higher levels of anti-ceramide IgM and diminished levels of 
anti-galactocerebroside antibodies in reactional compared to 
non-reactional patients
TABLe 5 | Continued
(Continued )
28
P
olycarpou et al.
Im
m
unology of E
rythem
a N
odosum
 Leprosum
Frontiers in Im
m
unology | w
w
w
.frontiersin.org
M
arch 2017 | Volum
e 8 | A
rticle 233
Reference; 
study site(s)
Study population Timing of 
sampling
MDT status eNL treatment 
status
Type of samples Measures Findings
Rojas et al. (50); 
Brazil β
19 ENL, 10 BL/LL non-
ENL patients, 13 family 
contacts; 15 healthy 
non-contacts
ND Both untreated 
patients and 
patients on MDT 
for 1-72 months
ND Serum Anti-PGL-I IgM, 
IgG responses to 
recombinant 10-kDa 
heat shock protein
IgM anti-PGL-I and IgG anti-10-kDa heat shock protein 
antibodies were constituents of the immune complexes in 
patients with ENL while free antibody levels did not differentiate 
between ENL and non-ENL patients
Beuria et al. 
(192); India
18 ENL, 44 BL/LL, 62 
BT/TT, 17 HC
ND Most patients 
on MDT
ND Serum IgG subclass levels to 
M. leprae sonicated 
antigens (MLSA) and 
PGL-I
ENL patients showed a significant fall in IgG3 antibody to MLSA 
and PGL-I compared to BL/LL leprosy controls
Freire et al. (193); 
Brazil
59 leprosy (including 12 
ENL), 60 HC
ND 11/12 ENL 
were on MDT 
and 1/12 with 
dapsone
ND Serum Anti-neutrophil 
cytoplasmic 
antibodies (ANCA)
ANCA are present in 28.8% of leprosy patients but are not 
related to vasculitis in the ENL reaction and are not a marker of a 
specific clinical from
Partida-Sanchez 
et al. (142); 
Mexico δ
9 ENL, 10 non-ENL 
leprosy, 10 HC
Beginning of 
reaction and after 
1 and 2 months of 
thalidomide 
All patients on 
MDT
Before thalidomide, 
second sample 
after 1 month 
of thalidomide 
and third after 
2 months
Plasma IgM and IgG antibody 
subclasses to M. 
leprae sonicated 
extract
ENL at the onset of reaction had slightly higher anti-M. leprae 
IgG1 and IgG2 antibodies compared to non-ENL but not 
statistically significant
Stefani et al. 
(194); Brazil
600 leprosy: 31 ENL, 
45 T1R, HC
Untreated Before MDT 
treatment
Untreated Serum IgM and IgG 
anti-PGL-I
Patients presenting with T1R or ENL at leprosy diagnosis have 
same level of IgM anti-PGL-I antibody response as leprosy 
patients without reactions at diagnosis
Beuria et al. 
(195); India
44 BL/LL, 62 TT/BT, 18 
ENL, 15 T1R, 17 HC
ND BL/LL: 90% on 
MDT
Steroids after 
collection of 
samples
Serum IgG1, IgG2, IgG3 and 
IgG4 to LAM
Reduction in IgG3 in ENL compared to active BL/LL
Higher IgG1 in ENL than T1R
TT/BT: mostly 
untreated
Hamerlinck et al. 
(196); Philippines, 
Netherlands
13 ENL, 22 T1R, 26 
leprosy unreactional, 
10 HC
Serial samples 
during MDT: 2 
ENL follow-up 
and received 
corticosteroids, 
14 leprosy free of 
reactions, 4 T1R 6, 
12, 18, 30 months 
during follow-up
13 ENL before 
MDT, 2 ENL 
during MDT
During ENL before 
treatment
Serum Neopterin T1R and ENL higher neopterin levels compared to non-reactional 
individuals
Corticosteroid treatment reduces levels of neopterin
Mahaisavariya 
et al. (197); 
Thailand
95 leprosy patients: 63 
non-reactional, 19 T1R, 
13 ENL
A biopsy at time of 
diagnosis and an 
additional biopsy 
later, in some 
cases at the time 
of reaction
ND Before 
antireactional 
treatment?
Skin Mast cells Reduction of mast cell counts in both T1R and ENL compared to 
non-reactional patients
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Schon et al. 
(198); Ethiopia
4 ENL, 5 T1R ND ENL cases: 
2 MDT 
untreated and 2 
MDT-treated
Steroids Urine Urinary levels of 
metabolites of NO
Urinary nitric oxide metabolites decreased significantly after 
steroid treatment
Antunes et al. 
(199); Brazil
3 ENL, 3 T1R First biopsy during 
reactional episode 
and second during 
remission
On MDT Thalidomide for 
ENL
Skin Neuropeptides; 
quantification of mast 
cells and their subsets
Increase mast cells in the inflammatory infiltrate of the reactional 
(both T1R and ENL) biopsies compared to non-reactional
Rada et al. (200); 
Venezuela
29 ENL, 19 MB not 
reactional, 11 PB, 
28 HC
Before treatment Untreated 
samples
Untreated samples Serum Nitrite/Nitrate levels Supernatants of PBMC from ENL patients significantly elevated 
levels of nitrite/nitrates compared to LL or tuberculoid leprosyPBMC
Sunderkotter 
et al. (201); Brazil
Skin Biopsies: 41 
non-reactional leprosy, 
8 ENL, 10 T1R; Serum 
samples: 16ENL, 5RR, 
7TT, 13BT/BB/LL, 
19 HC
Untreated samples Skin biopsies: 
42 untreated 
non-reactional 
leprosy
Before treatment 
with steroids or 
thalidomide
Serum
Skin
MRP8, MRP14 Increase of serum levels of MRP8 and MRP14 in ENL
Higher percentage of MRP8+ and MRP14+ cells in ENL skin 
lesions than non-reactional
8 ENL of which 
5 MDT
Nigam et al. 
(202); India
80 leprosy: 10 ENL and 
10 T1R; 20 HC
ND ND ND Serum Deaminase Deaminase levels were higher in patients with reaction
Villahermosa 
et al. (134); 
Philippines γ, δ
22 ENL Before thalidomide 
administration 
and at study 
weeks 3 and 7 
during thalidomide 
treatment
MDT was 
continued 
during the study
Samples untreated 
for antireactional 
drugs and during 
thalidomide 
treatment
Urine Neopterin ENL higher neopterin values in urine than HC
Iyer et al. (143); 
Indonesia δ
131 leprosy patients 
(44 ENL), 112 HC
ND Patients were 
classified 
irrespective of 
MDT status
Prednisolone to 
treat reactions
Plasma Neopterin Neopterin no significant difference between ENL and non-ENL
Mohanty et al. 
(203); India
14 ENL before and 
after resolution of ENL, 
5 LL
Before 
commencing 
antireactional 
therapy and after 
resolution of ENL
All patients on 
MDT
Before 
commencing 
antireactional 
treatment
Urine Urinary nitric oxide 
metabolites
Urinary nitric oxide metabolite higher in ENL compared to non-
reactional LL
These levels were reduced with resolution of reaction following 
antireactional therapy
Santos et al. 
(204); Brazil
8 leprosy: 3 ENL ND MDT during the 
study: length of 
MDT described
Thalidomide during 
the study
PBMC B7-1 expression (flow 
cytometry and IHC)
Higher B7 expression in ENL and T1R patients than non-
reactional in both PBMC and cutaneous lesionsSkin
(Continued )
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Silva et al. (205); 
Brazil
25 leprosy: 5 ENL and 
8 T1R
0, 2, 4, 6, and 
12 months of MDT
All patients on 
MDT
Untreated Plasma PGL-I levels Serum PGL-I levels did not differ significantly between ENL and 
non-ENL
Neopterin No significant correlation of neopterin between ENL and 
non-ENL
Brito Mde et al. 
(206); Brazil
104 reactions after 
completion of MDT (44 
ENL), 104 with no post-
treatment reactions 
(8 ENL)
ND All patients were 
treated with 
MDT; half had 
finished MDT
ND Plasma ML flow (IgM 
anti-PGL-I positive 
serology)
The patients with positive serology after MDT presented a 10.4 
fold greater chance of developing post-treatment reactions (ENL 
or T1R)
Iyer et al. (207); 
Indonesia
78 leprosy (36 ENL and 
3 T1R), 36 HC
ND 30 untreated 
and 48 treated 
patients
Reactions were 
treated using 
prednisolone
Serum Chitotriocidase Serum chitotriosidase activity elevated in ENL compared with HC 
but not with non-ENL leprosy
Skin Significant decline of serum chitotriosidase following 
corticosteroid treatment in ENL
Lee et al. (24); 
USA α
6 ENL, 7 LL ND ND ND Skin Microarrays and gene 
expression; IHC for 
E-selectin
Upregulation of gene expression: in ENL lesions of the selectin 
family of adhesion molecules
IHC: higher levels of E-selectin in ENL lesions
Massone et al. 
(116); Brazil γ
20 leprosy biopsies 
(3 ENL)
Biopsies at the 
time of diagnosis 
10, 12 and 
13 months after 
beginning of 
MDT for LL
Untreated Skin Presence, frequency 
and distribution 
of plasmacytoid 
dendritic cells
CD123 expression was observed in 2/3 ENL biopsies
Rada et al. (135); 
Venezuela γ
81 LL, 41 BL, 41 BB, 
3% BT
ND ND ND Blood Serological 
immunological tests to 
various mycobacterial 
proteins
Mean antibody values against complete mycobacterial proteins 
higher in non-reactional individuals
Teles et al. (176); 
Brazil δ
32 leprosy: 10 ENL, 
8 T1R
4 ENL patients 
before and during 
reaction biopsy 
samples
All patients were 
receiving MDT
ND Skin MMP-2, MMP-9, 
TIMP-1
RT-PCR for MMP-2 and MMP-9 versus TIMP-1 in ENL 
sequential samples in 4 ENL patients: TNF-α, MMP-2 and MMP-
9 mRNA enhanced IHC and confocal microscopy: absence of 
MMP positivity in ENL epidermis ELISA in sera of ENL: elevated 
MMP-9 but not TIMP-1 compared to non-reactional patients
Serum
Jadhav et al. 
(149); India δ
303 MB followed up for 
2 years: 5 ENL
Serum samples 
at the time of 
recruitment
Newly registered 
MB patients: no 
MDT
Untreated Serum Antibodies to PGL-I, 
LAM, ceramide, S100 
No statistically significant outcome for ENL
Lockwood et al. 
(178); India δ
303 new MB leprosy 
(13 ENL)
Skin biopsies at 
enrollment
Before MDT 
treatment 
started
Before 
antireactional 
treatment
Skin Immunostaining for 
CD68 and iNOS
Reactional biopsies had significantly fewer CD68+ cells than 
non-reactional
Nearly all biopsies in the LL group had CD68+ cells present and 
these were not altered in ENL
Nerve ENL showed some iNOS staining but not significant differences 
with non-ENL
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Martiniuk et al. 
(179); Nepal and 
USA δ
7 ENL Pre- and post-
treatment with 
thalidomide
ND Pre- and post- 
treatment with 
thalidomide
Skin RT-PCR for hRORγT, 
hCD70, hCD27, 
hPLZF-1, hCTLA4, 
hAHR, hiNOS2, 
hARNT, hIDO, hGARP, 
hCD46
Reduction in CD70, GARP, IDO and increase of RORγT, ARNT 
following thalidomide treatment
Singh et al. (208); 
India
240 leprosy: 19 ENL, 
69 BL/LL 
ND ND ND Serum IgG antibodies against 
keratin
No significant difference in ENL
Dupnik et al. (58); 
Brazil β, δ
11 ENL, 11 T1R, 
19 leprosy controls 
without reactions for 
microarray; additional 
28 leprosy (6 ENL, 11 
T1R, 11 non-reactional) 
for qPCR validation; 3 
ENL for IHC
ND 3/11 ENL 
pre-treatment, 
2/11 ENL on 
treatment and 
6/11 post-
treatment; 
leprosy controls 
matched 
for stage of 
treatment
Excluded patients 
on steroids 
within 7 days 
and thalidomide 
within 28 days of 
enrollment
PBMC Microarray and qPCR 
for transcriptional 
profile of PBMC; 
Flow cytometry for 
monocyte populations 
Top 3 KEGG pathways in ENL were S.aureus infection, SLE, 
cytokine-cytokine receptor interaction
No significant difference in the proportion of circulating 
monocytes between reactional and non-reactional PBMC
Mandal et al. 
(209); India
15 reactional (both ENL 
and T1R), 15 HC
ND ND ND PBMC Vitamin D receptor 
(VDR) mRNA 
All the individuals with low VDR expression manifested ENL
Dias et al. (80); 
Brazil δ
30 ENL, 24 BL/LL, 
31 HC
Upon diagnosis of 
reaction
BL/LL before 
MDT but most 
ENL on MDT
Before treatment 
with thalidomide or 
steroids
PBMC 
(monocytes, 
B-cells, pDCs)
Expression of TLR9 Skin lesions and PBMC of ENL express higher levels of TLR-9
Skin
Schmitz et al. 
(25); Brazil α 
62 leprosy: 22 ENL, 
16 HC
ENL: before 
and 7 days after 
thalidomide
Patients before 
and after MDT
Before and after 
thalidomide
Skin CD64 expression by 
qPCR and IHC
CD64 mRNA and protein expressed in ENL lesions
Thalidomide reduced CD64 expression
α, also in Table 1; β, also in Table 2; γ, also in Table 3; δ, also in Table 4.
BB, mid-borderline leprosy; BL, borderline lepromatous leprosy; BT, borderline tuberculoid leprosy; ENL, erythema nodosum leprosum; HC, healthy controls; ICAM-1, keratinocyte intracellular adhesion molecule 1; ICs, immune 
complexes; LAM, lipoarabinomannan; LL, lepromatous leprosy polar; MLSA, M. leprae sonicated antigens; ND, not described; PGL I, phenolic glycolipid I; SLE, systemic lupus erythematosus; TB, tuberculosis; TT, tuberculoid leprosy; 
polar,%GO, proportion of oligosaccharide chains on the Fc fragment of IgG which terminate with N-acetylglucosamine and not galactose.
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New Suggested Pathogenetic 
Mechanisms
Two recent studies of gene expression provide evidence of activa-
tion of novel molecular pathways in ENL.
Lee et al performed bioinformatic pathways analysis of gene 
expression profiles in leprosy skin lesions and found “cell move-
ment” as the top biological pathway characterizing ENL (24). 
The study further described a neutrophil recruitment pathway 
including genes of key molecules that mediate neutrophil bind-
ing to endothelial cells (24). This neutrophil recruitment pathway 
characterizing ENL was inhibited by thalidomide (24). Consistent 
with these findings is a study of transcriptional profiles in PBMC 
of leprosy patients by Dupnik et al which identified “granulocyte 
adhesion and diapedesis” as one of the top canonical pathways 
characterizing ENL (58). Dupnik et  al. identified 517 differen-
tially expressed genes in patients with ENL (58). The pathway 
analysis revealed that the top three Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathways that changed in ENL were 
Staphylococcus aureus infection, systemic lupus erythematosus 
(SLE), and cytokine-cytokine receptor interaction, while the 
complement and coagulation pathway was also associated with 
ENL (58). CCL5 was the most significant upstream regulator in 
the array followed by IFN-γ (58). Transcripts uniquely increased 
in ENL included the complement receptors C3AR1 and C5AR1 
while uniquely decreased transcripts in ENL included IL-10 and 
cytotoxic T-lymphocyte associates protein 4 (CTLA-4), modula-
tors of T-cell responses (58). Hepcidin, catholicidin, antimicrobial 
peptides, C1q, and defencins had also an increased expression in 
ENL, while CCL2, CCL3, and SOD2 could be potential biomarkers 
for ENL (58). Transcripts increased in PBMC from ENL patients 
also included FcγR1 (CD64), FPR1, and FPR2, which recognize 
formylated peptides produced by bacteria triggering receptor 
on myeloid cells 1 (TREM1) and the related molecule triggering 
receptor expressed on myeloid cells-like 1 (TREML-1) (58).
The microarray studies performed in skin lesions and PBMC 
have generated a long list of candidate genes that regulate immune 
function to be associated with ENL. These merit further research.
LiMiTATiONS OF THe SYSTeMATiC 
Review
PubMed was the only database used to identify eligible studies. 
This will have resulted in studies published in journals not listed 
in PubMed being omitted from our review. A search of gray litera-
ture may also have contributed data which may have influenced 
our conclusions. The high heterogeneity of included studies in 
terms of study questions and outcomes and the different method-
ologies used meant that a meta-analysis was not possible.
MeTHODOLOGiCAL CONSiDeRATiONS 
OF THe STUDieS iNCLUDeD iN THe 
SYSTeMATiC Review
Many of the studies of immunological features of ENL contain 
significant limitations in both design and reporting. Most seri-
ously 66% of the studies did not have a case definition of ENL.
More than 70% of studies sampled individuals at a single time 
point. Sampling at two time points was seen in 21.2% of studies, 
3 time points in 2.7% of studies, whereas 4 or more time points 
was described in only 5.5% of studies. Some studies did not 
have appropriate controls- patients with uncomplicated BL and 
LL. Although 93.2% of studies used BL/LL patients as controls, 
the remaining 6.8% of studies used other control groups such 
as healthy volunteers or leprosy contacts or tuberculoid leprosy 
patients or patients with Type 1 reaction. Often the controls were 
not matched for age, sex or treatment status. Controls should be 
matched for age and sex since these factors may influence T cell 
and neutrophil numbers and functions (214–216) as well as TNF-
α and other cytokine levels (217).
ENL is a condition that can be acute, recurrent, or chronic, 
and therefore, the timing of sample collection is crucial. No 
information on the timing of the sampling is described in 54.8% 
of all studies. The importance of timing for sample collection 
during ENL could explain the discrepancies observed in multi-
ple studies as has been suggested in the studies addressing the 
role of neutrophils in ENL. Studies using serial sampling yield 
more meaningful data compared to cross-sectional studies. The 
interval between time points is important and needs to be kept as 
consistent as possible for all study subjects.
Only one study matched BL/LL controls and ENL cases for 
length of MDT. Patients may develop ENL prior to the diagnosis 
of leprosy, during MDT or after successful completion of MDT. 
MDT may affect the immune status of leprosy patients and thus 
the matching of cases and controls for this variable is important. 
Two of the components of MDT, dapsone and clofazimine, have 
been associated with alterations in neutrophil and lymhocyte 
function (218–220). Dapsone stimulates neutrophil migration 
(218) and inhibits production of Prostaglandin E2 by neutrophils 
(220). In addition, dapsone inhibits lymphocyte transformation 
(218). On the other hand, clofazimine enhances production of 
Prostaglandin E2 by neutrophils (220). Dapsone and anti-dapsone 
antibodies have been identified in circulating ICs of leprosy 
patients (221). Circulating cytokine and chemokine levels also 
change with MDT (165, 222, 223). In addition, gene expression 
studies could be affected by MDT since the MDT component 
rifampicin may modify the expression of certain housekeeping 
genes (224). A total of 30.8% of studies did not report the MDT 
status of their cases or controls, 12.3% collected untreated patient 
samples, whereas 56.2% collected patient samples at various 
stages of MDT.
The effect of immunosuppressive drugs used to treat ENL 
on the findings of studies is an important factor which should 
be considered. In 37.7% of studies, there was no reporting of 
whether participants were on ENL treatment when samples 
were collected. Treatment with corticosteroids affects T-cells 
and neutrophil function (225, 226) and also gene expression 
studies by influencing housekeeping genes (224). Treatment 
with thalidomide may increase the neutrophil numbers, at least 
partially through differentially modulating the surface expres-
sion of markers CD18 and CD44 by the neutrophils in the bone 
marrow and the spleen (227). Thalidomide treatment may also 
affect T-cell functions by suppressing CD4+ T-cell proliferation 
while increasing their conversion to CD4+FoxP3+ Tregs (228). 
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further complicate the phenotype of ENL.
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Moreover, thalidomide treatment may reduce cytokine levels 
(229). Less than half (34.2%) of studies indicate that samples were 
obtained prior to the start of ENL treatment.
Only 17.8% of all studies collected samples from more than one 
system, while samples from both blood and skin were described 
in only 12.3% of all studies.
FUTURe STUDY DeSiGN
Studies of ENL may be difficult to design and conduct. In addi-
tion, no animal model of ENL is available. Obtaining sufficient 
numbers of patients so that studies are adequately powered is 
difficult unless multicenter studies are performed which increase 
the logistical complexity and cost of the research. Patients are 
often on treatment (both MDT and immunosuppression) which 
may influence the study outcomes.
A large cohort study of newly diagnosed patients with BL and 
LL would be optimal in allowing matching of cases and controls. 
Some BL/LL patients who have not developed ENL at enrollment 
in the study should be recruited and followed until they develop 
the disorder. Detailed clinical information which includes demo-
graphic data, ENL severity using a robust measure, treatment 
status, in conjunction with well-timed and documented speci-
men collection (preferably of blood and skin), effective specimen 
storage, and transportation. ENL is a systemic disease and ideally 
samples from more than one system, i.e., both blood and skin 
should be obtained where appropriate. Well-designed laboratory 
experiments using a wide range of techniques should be used to 
interrogate such important specimens.
CONCLUSiON
Figure 2 gives an overview of the immunology of ENL.
Our understanding of the causes of ENL is limited. The factors 
that initiate and/or sustain it might help to identify strategies to 
prevent or control the associated inflammation.
There is some evidence to support a role for neutrophils and 
ICs/complement in the inflammation associated with ENL; 
however, their role in the initiation of ENL remains unclear. The 
increase of TNF-α and other pro-inflammatory cytokines during 
ENL has been shown in multiple investigations, while suppression 
of TNF-α leads to clinical improvement. T-cell subsets appear to 
be important in ENL since multiple reports describe an increased 
CD4+/CD8+ ratio in ENL patients compared to BL/LL controls.
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New technologies such as microarray studies pave the way 
and may lead to novel immunological pathways associated with 
ENL. Further research of the association of ENL with patho-
physiological pathways such as the SLE pathway or the S. aureus 
infection pathway may improve our understanding of the disor-
der and potentially lead to novel therapeutic strategies. There are 
still large gaps in our understanding of this severe complication 
of leprosy despite the large number of studies examining the 
immunology of ENL. A systems biology approach may provide 
new insights.
This systematic review has highlighted the complex interac-
tions at play in ENL and the difficulty in elucidating the various 
inflammatory pathways. We should rise to the challenge of 
understanding how these mechanisms operate and interact so 
that we can improve the treatment of patients with ENL.
AUTHOR CONTRiBUTiONS
AP and SW were responsible for the study concept and design; 
made critical revision of the manuscript for important intel-
lectual content. AP was responsible for acquisition, analysis, and 
interpretation of data and for drafting the manuscript. AP, SW, 
and DL edited the manuscript.
ACKNOwLeDGMeNTS
We would like to thank Anna and Andreas Goulielmos for proof 
reading and grammatical error corrections.
FUNDiNG
This work was supported by Hospital and Homes of St. Giles.
ReFeReNCeS
1. Britton WJ, Lockwood DN. Leprosy. Lancet (2004) 363(9416):1209–19. 
doi:10.1016/S0140-6736(04)15952-7 
2. Ridley DS, Jopling WH. Classification of leprosy according to immunity. 
A five-group system. Int J Lepr Other Mycobact Dis (1966) 34(3):255–73. 
3. Turk JL, Waters MF. Cell-mediated immunity in patients with leprosy. Lancet 
(1969) 2(7614):243–6. doi:10.1016/S0140-6736(69)90009-9 
4. Moran CJ, Ryder G, Turk JL, Waters MF. Evidence for circulating immune 
complexes in lepromatous leprosy. Lancet (1972) 2(7777):572–3. doi:10.1016/
S0140-6736(72)91962-9 
5. Scollard DM, Smith T, Bhoopat L, Theetranont C, Rangdaeng S, Morens DM. 
Epidemiologic characteristics of leprosy reactions. Int J Lepr Other Mycobact 
Dis (1994) 62(4):559–67. 
6. Walker SL, Balagon M, Darlong J, Doni SN, Hagge DA, Halwai V, et al. ENLIST 
1: an international multi-centre cross-sectional study of the clinical features 
of erythema nodosum leprosum. PLoS Negl Trop Dis (2015) 9(9):e0004065. 
doi:10.1371/journal.pntd.0004065 
7. Mabalay MC, Helwig EB, Tolentino JG, Binford CH. The histopathology 
and histochemistry of erythema nodosum leprosum. Int J Lepr (1965) 
33:28–49. 
8. Anthony J, Vaidya MC, Dasgupta A. Ultrastructure of skin in erythema 
nodosum leprosum. Cytobios (1983) 36(141):17–23. 
9. Murphy GF, Sanchez NP, Flynn TC, Sanchez JL, Mihm MC Jr, Soter NA. 
Erythema nodosum leprosum: nature and extent of the cutaneous micro-
vascular alterations. J Am Acad Dermatol (1986) 14(1):59–69. doi:10.1016/
S0190-9622(86)70008-X 
10. Sehgal VN, Gautam RK, Koranne RV, Beohar PC. The histopathology of 
type I (lepra) and type II (ENL) reactions in leprosy. Indian J Lepr (1986) 
58(2):240–3. 
11. Adhe V, Dongre A, Khopkar U. A retrospective analysis of histopathology 
of 64 cases of lepra reactions. Indian J Dermatol (2012) 57(2):114–7. 
doi:10.4103/0019-5154.94278 
12. Sarita S, Muhammed K, Najeeba R, Rajan GN, Anza K, Binitha MP, et al. 
A study on histological features of lepra reactions in patients attending the 
Dermatology Department of the Government Medical College, Calicut, 
Kerala, India. Lepr Rev (2013) 84(1):51–64. 
13. Job CK, Gude S, Macaden VP. Erythema nodosum leprosum. A clinico- 
pathologic study. Int J Lepr (1964) 32:177–84. 
14. Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, et al. 
Clinical course of erythema nodosum leprosum: an 11-year cohort study in 
Hyderabad, India. Am J Trop Med Hyg (2006) 74(5):868–79. 
15. Chandler DJ, Hansen KS, Mahato B, Darlong J, John A, Lockwood 
DN. Household costs of leprosy reactions (ENL) in rural India. 
PLoS Negl Trop Dis (2015) 9(1):e0003431. doi:10.1371/journal.pntd. 
0003431 
16. Walker SL, Lebas E, Doni SN, Lockwood DN, Lambert SM. The mortality 
associated with erythema nodosum leprosum in ethiopia: a retrospective 
hospital-based study. PLoS Negl Trop Dis (2014) 8(3):e2690. doi:10.1371/
journal.pntd.0002690 
17. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. 
Preferred reporting items for systematic review and meta-analysis protocols 
(PRISMA-P) 2015: elaboration and explanation. BMJ (2015) 349:g7647. 
doi:10.1136/bmj.g7647 
18. Kruger P, Saffarzadeh M, Weber AN, Rieber N, Radsak M, von Bernuth 
H, et  al. Neutrophils: between host defence, immune modulation, and 
tissue injury. PLoS Pathog (2015) 11(3):e1004651. doi:10.1371/journal.
ppat.1004651 
19. Leliefeld PH, Koenderman L, Pillay J. How neutrophils shape adaptive 
immune responses. Front Immunol (2015) 6:471. doi:10.3389/fimmu.2015. 
00471 
20. Abalos RM, Tolentino JG, Bustillo CC. Histochemical study of erythema 
nodosum leprosum (ENL) lesions. Int J Lepr Other Mycobact Dis (1974) 
42(4):385–91. 
21. Hussain R, Lucas SB, Kifayet A, Jamil S, Raynes J, Uqaili Z, et al. Clinical 
and histological discrepancies in diagnosis of ENL reactions classified by 
assessment of acute phase proteins SAA and CRP. Int J Lepr Other Mycobact 
Dis (1995) 63(2):222–30. 
22. Waters MF, Turk JL, Wemambu SN. Mechanisms of reactions in leprosy. Int 
J Lepr Other Mycobact Dis (1971) 39(2):417–28. 
23. Pepler WJ, Kooij R, Marshall J. The histopathology of acute panniculitis 
nodosa leprosa (erythema nodosum leprosum). Int J Lepr (1955) 23(1): 
53–60. 
24. Lee DJ, Li H, Ochoa MT, Tanaka M, Carbone RJ, Damoiseaux R, et  al. 
Integrated pathways for neutrophil recruitment and inflammation in leprosy. 
J Infect Dis (2010) 201(4):558–69. doi:10.1086/650318 
25. Schmitz V, Prata RB, Barbosa MG, Mendes MA, Brandao SS, Amadeu TP, 
et  al. Expression of CD64 on circulating neutrophils favoring systemic 
inflammatory status in erythema nodosum leprosum. PLoS Negl Trop Dis 
(2016) 10(8):e0004955. doi:10.1371/journal.pntd.0004955 
26. Hogg N. The structure and function of Fc receptors. Immunol Today (1988) 
9(7–8):185–7. doi:10.1016/0167-5699(88)91206-6 
27. Herra CM, Keane CT, Whelan A. Increased expression of Fc gamma 
receptors on neutrophils and monocytes may reflect ongoing bacterial 
infection. J Med Microbiol (1996) 44(2):135–40. doi:10.1099/00222615-44- 
2-135 
28. Song SH, Kim HK, Park MH, Cho HI. Neutrophil CD64 expression is 
associated with severity and prognosis of disseminated intravascular coag-
ulation. Thromb Res (2008) 121(4):499–507. doi:10.1016/j.thromres.2007. 
05.013 
29. Buckle AM, Hogg N. The effect of IFN-gamma and colony-stimulating 
factors on the expression of neutrophil cell membrane receptors. J Immunol 
(1989) 143(7):2295–301. 
30. Voorend CG, Post EB. A systematic review on the epidemiological data of 
erythema nodosum leprosum, a type 2 leprosy reaction. PLoS Negl Trop Dis 
(2013) 7(10):e2440. doi:10.1371/journal.pntd.0002440 
36
Polycarpou et al. Immunology of Erythema Nodosum Leprosum
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 233
31. Goihman-Yahr M, Rodriguez-Ochoa G, Aranzazu N, Convit 
J. Polymorphonuclear activation in leprosy. I. Spontaneous and endotox-
in-stimulated reduction of nitroblue tetrazolium: effects of serum and 
plasma on endotoxin-induced activation. Clin Exp Immunol (1975) 20(2): 
257–64. 
32. Sher R, Anderson R, Glover A, Wadee AA. Polymorphonuclear cell function 
in the various polar types of leprosy and erythema nodosum leprosum. Infect 
Immun (1978) 21(3):959–65. 
33. Oliveira RB, Moraes MO, Oliveira EB, Sarno EN, Nery JA, Sampaio EP. 
Neutrophils isolated from leprosy patients release TNF-alpha and exhibit 
accelerated apoptosis in vitro. J Leukoc Biol (1999) 65(3):364–71. 
34. Wiggins RC, Cochrane CG. Immune-complex-mediated biologic effects. 
N Engl J Med (1981) 304(9):518–20. doi:10.1056/NEJM198102263040904 
35. Hoiby N, Doring G, Schiotz PO. The role of immune complexes in the 
pathogenesis of bacterial infections. Annu Rev Microbiol (1986) 40:29–53. 
doi:10.1146/annurev.mi.40.100186.000333 
36. Schifferli JA, Ng YC, Peters DK. The role of complement and its receptor in 
the elimination of immune complexes. N Engl J Med (1986) 315(8):488–95. 
doi:10.1056/NEJM198608213150805 
37. Wemambu SN, Turk JL, Waters MF, Rees RJ. Erythema nodosum lepro-
sum: a clinical manifestation of the arthus phenomenon. Lancet (1969) 
2(7627):933–5. doi:10.1016/S0140-6736(69)90592-3 
38. Anthony J, Vaidya MC, Dasgupta A. Immunological methods employed in 
an attempt to induce erythema nodosum leprosum (ENL) in mice. Lepr India 
(1978) 50(3):356–62. 
39. Ridley MJ, Ridley DS. The immunopathology of erythema nodosum 
leprosum: the role of extravascular complexes. Lepr Rev (1983) 54(2): 
95–107. 
40. Andreoli A, Brett SJ, Draper P, Payne SN, Rook GA. Changes in circulating 
antibody levels to the major phenolic glycolipid during erythema nodo-
sum leprosum in leprosy patients. Int J Lepr Other Mycobact Dis (1985) 
53(2):211–7. 
41. Chakrabarty AK, Maire M, Saha K, Lambert PH. Identification of compo-
nents of IC purified from human sera. II. Demonstration of mycobacterial 
antigens in immune complexes isolated from sera of lepromatous patients. 
Clin Exp Immunol (1983) 51(2):225–31. 
42. Furukawa F, Ozaki M, Imamura S, Yoshida H, Pinrat A, Hamashima 
Y. Associations of circulating immune complexes, clinical activity, and 
bacterial index in Japanese patients with leprosy. Arch Dermatol Res (1982) 
274(1–2):185–8. doi:10.1007/BF00510372 
43. Rojas-Espinosa O, Mendez-Navarrete I, Estrada-Parra S. Presence of C1q-
reactive immune complexes in patients with leprosy. Clin Exp Immunol 
(1972) 12(2):215–23. 
44. Wager O, Penttinen K, Almeida JD, Opromolla DV, Godal T, Kronvall G. 
Circulating complexes in leprosy studied by the platelet aggregation test. 
The platelet aggregation test and its relation to the Rubino test and other 
sero-immunological parameters in 135 patients with leprosy. Clin Exp 
Immunol (1978) 34(3):326–37. 
45. Geniteau M, Adam C, Verroust P, Pasticier A, Saimot G, Coulaud JP, et al. 
[Immune complexes and complement in leprosy (author’s transl)]. Nouv 
Presse Med (1981) 10(45):3697–700. 
46. Bjorvatn B, Barnetson RS, Kronvall G, Zubler RH, Lambert PH. Immune 
complexes and complement hypercatabolism in patients with leprosy. Clin 
Exp Immunol (1976) 26(3):388–96. 
47. Jayapal N, Shanmugasundaram N, Thomas PA, Valli PR, Thyagarajan SP, 
Subramanian S. A simple method to quantitate circulating immune com-
plexes in different diseases. Indian J Pathol Microbiol (1989) 32(1):33–9. 
48. Ramanathan VD, Sharma P, Ramu G, Sengupta U. Reduced complement- 
mediated immune complex solubilization in leprosy patients. Clin Exp 
Immunol (1985) 60(3):553–8. 
49. Ramanathan VD, Tyagi P, Ramanathan U, Katoch K, Sengupta U, Ramu 
G. Persistent reduced solubilization of immune complexes in lepromatous 
leprosy patients with reactions. Int J Lepr Other Mycobact Dis (1991) 
59(1):5–11. 
50. Rojas RE, Demichelis SO, Sarno EN, Segal-Eiras A. IgM anti-phenolic 
glycolipid I and IgG anti-10-kDa heat shock protein antibodies in sera and 
immune complexes isolated from leprosy patients with or without erythema 
nodosum leprosum and contacts. FEMS Immunol Med Microbiol (1997) 
19(1):65–74. doi:10.1111/j.1574-695X.1997.tb01073.x 
51. Tung KS, Kim B, Bjorvatn B, Kronvall G, McLaren LC, Williams RC Jr. 
Discrepancy between Clq deviation and Raji cell tests in detection of 
circulating immune complexes in patients with leprosy. J Infect Dis (1977) 
136(2):216–21. doi:10.1093/infdis/136.2.216 
52. Tyagi P, Ramanathan VD, Girdhar BK, Katoch K, Bhatia AS, Sengupta U. 
Activation of complement by circulating immune complexes isolated from 
leprosy patients. Int J Lepr Other Mycobact Dis (1990) 58(1):31–8. 
53. Tyagi P, Patil SA, Girdhar BK, Katoch K, Sengupta U. Suppressive effect of 
circulating immune complexes from leprosy patients on the lymphocyte 
proliferation induced by M. leprae antigens in healthy responders. Int J Lepr 
Other Mycobact Dis (1992) 60(4):562–9. 
54. Valentijn RM, Faber WR, Lai AFRF, Chan Pin Jie JC, Daha MR, van 
Es LA. Immune complexes in leprosy patients from an endemic and a 
nonendemic area and a longitudinal study of the relationship between 
complement breakdown products and the clinical activity of erythema 
nodosum leprosum. Clin Immunol Immunopathol (1982) 22(2):194–202. 
doi:10.1016/0090-1229(82)90037-X 
55. Penttinen K, Myllyla G, Vaheri A, Vesikari T, Kaariainen L. The platelet aggre-
gation test (PA) as an immunological method in virology. Prog Immunobiol 
Stand (1970) 4:672–5. 
56. Yanase K, Imamura S. Detection of circulating immune complexes in some 
skin diseases by platelet aggregation test. Br J Dermatol (1979) 100(2):227–8. 
doi:10.1111/j.1365-2133.1979.tb05567.x 
57. Rojas RE, Segal-Eiras A. Characterization of circulating immune com-
plexes in leprosy patients and their correlation with specific antibodies 
against Mycobacterium leprae. Clin Exp Dermatol (1997) 22(5):223–9. 
doi:10.1046/j.1365-2230.1997.2620675.x 
58. Dupnik KM, Bair TB, Maia AO, Amorim FM, Costa MR, Keesen TS, et al. 
Transcriptional changes that characterize the immune reactions of leprosy. 
J Infect Dis (2015) 211(10):1658–76. doi:10.1093/infdis/jiu612 
59. de Azevedo MP, de Melo PH. A comparative study of the complementary 
activity of serum in the polar forms of leprosy and in the leprosy reaction. Int 
J Lepr Other Mycobact Dis (1966) 34(1):34–8. 
60. Anthony J, Vaidya MC, Dasgupta A. Immunoglobulin deposits in erythema 
nodosum leprosum (ENL). Hansen Int (1978) 3(1):12–7. 
61. Lange K, Wasserman E, Slobody LB. The significance of serum complement 
levels for the diagnosis and prognosis of acute and subacute glomerulo-
nephritis and lupus erythematosus disseminatus. Ann Intern Med (1960) 
53:636–46. doi:10.7326/0003-4819-53-4-636 
62. Lewis EJ, Carpenter CB, Schur PH. Serum complement component 
levels in human glomerulonephritis. Ann Intern Med (1971) 75(4):555–60. 
doi:10.7326/0003-4819-75-4-555 
63. Ohi H, Tamano M. Decreased apolipoprotein levels are associated with 
decreased complement levels in acute glomerulonephritis. Nephron (2001) 
88(4):389–90. doi:10.1159/000046028 
64. Baatrup G, Petersen I, Kappelgaard E, Jepsen HH, Svehag SE. Complement-
mediated solubilization of immune complexes. Solubilization inhibition 
and complement factor levels in SLE patients. Clin Exp Immunol (1984) 
55(2):313–8. 
65. Grevink ME, Horst G, Limburg PC, Kallenberg CG, Bijl M. Levels of com-
plement in sera from inactive SLE patients, although decreased, do not influ-
ence in  vitro uptake of apoptotic cells. J Autoimmun (2005) 24(4):329–36. 
doi:10.1016/j.jaut.2005.03.004 
66. Schifferli JA, Morris SM, Dash A, Peters DK. Complement-mediated solubili-
zation in patients with systemic lupus erythematosus, nephritis or vasculitis. 
Clin Exp Immunol (1981) 46(3):557–64. 
67. de Messias IJ, Santamaria J, Brenden M, Reis A, Mauff G. Association 
of C4B deficiency (C4B*Q0) with erythema nodosum in leprosy. 
Clin Exp Immunol (1993) 92(2):284–7. doi:10.1111/j.1365-2249.1993. 
tb03393.x 
68. Hauptmann G, Tappeiner G, Schifferli JA. Inherited deficiency of the 
fourth component of human complement. Immunodefic Rev (1988) 
1(1):3–22. 
69. Gelber RH, Drutz DJ, Epstein WV, Fasal P. Clinical correlates of C1Q-
precipitating substances in the sera of patients with leprosy. Am J Trop Med 
Hyg (1974) 23(3):471–5. 
70. Izumi S, Sugiyama K, Matsumoto Y, Nagai T. Numerical changes in T cell 
subsets (T gamma and T mu) in leprosy patients. Microbiol Immunol (1980) 
24(8):733–40. doi:10.1111/j.1348-0421.1980.tb02874.x 
37
Polycarpou et al. Immunology of Erythema Nodosum Leprosum
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 233
71. Harikrishan S, Balakrishnan S, Bhatia VN. Serum immunoglobulin profile 
and C3 level in lepromatous leprosy patients. Lepr India (1982) 54(3):454–60. 
72. Saha K, Chakraborty AK, Sharma V, Sehgal VN. An appraisal of third 
complement component (C3) and breakdown product (C3d) in erythema 
nodosum leprosum (ENL). Lepr Rev (1982) 53(4):253–60. 
73. Mshana RN, Humber DP, Belehu A, Harboe M. Immunohistological studies 
of skin biopsies from patients with lepromatous leprosy. J Clin Immunol 
(1983) 3(1):22–9. doi:10.1007/BF00919135 
74. Ramanathan VD, Parkash O, Ramu G, Parker D, Curtis J, Sengupta U, et al. 
Isolation and analysis of circulating immune complexes in leprosy. Clin Immunol 
Immunopathol (1984) 32(3):261–8. doi:10.1016/0090-1229(84)90270-8 
75. Saha K, Chakrabarty AK, Sharma VK, Sehgal VN. Polyethylene glycol pre-
cipitates in serum during and after erythema nodosum leprosum – study of 
their composition and anticomplementary activity. Int J Lepr Other Mycobact 
Dis (1984) 52(1):44–8. 
76. Sehgal VN, Gautam RK, Sharma VK. Immunoprofile of reactions in leprosy. 
Int J Dermatol (1986) 25(4):240–4. doi:10.1111/j.1365-4362.1986.tb02233.x 
77. Chakrabarty AK, Kashyap A, Sehgal VN, Saha K. Solubilization of preformed 
immune complexes in sera of patients with type 1 and type 2 lepra reactions. 
Int J Lepr Other Mycobact Dis (1988) 56(4):559–65. 
78. Rao TD, Rao PR. Serum immune complexes in erythema nodosum leprosum 
reactions of leprosy. Indian J Lepr (1988) 60(2):189–95. 
79. Sehgal VN, Sharma V, Sharma VK. The effect of anti-reactional drugs on 
complement components in the type II, erythema nodosum leprosum, 
reaction. Br J Dermatol (1988) 119(2):255–8. doi:10.1111/j.1365-2133.1988.
tb03209.x 
80. Dias AA, Silva CO, Santos JP, Batista-Silva LR, Acosta CC, Fontes AN, 
et  al. DNA sensing via TLR-9 constitutes a major innate immunity path-
way activated during erythema nodosum leprosum. J Immunol (2016) 
197(5):1905–13. doi:10.4049/jimmunol.1600042 
81. Sehgal VN, Sharma V, Sharma VK. Comprehensive evaluation of com-
plement components in the course of type I (Lepra) and type II (ENL) 
reactions. Int J Dermatol (1989) 28(1):32–5. doi:10.1111/j.1365-4362.1989. 
tb01306.x 
82. Scollard DM, Bhoopat L, Kestens L, Vanham G, Douglas JT, Moad J. Immune 
complexes and antibody levels in blisters over human leprosy skin lesions 
with or without erythema nodosum leprosum. Clin Immunol Immunopathol 
(1992) 63(3):230–6. doi:10.1016/0090-1229(92)90227-F 
83. Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and 
the not-so-helpful. Cancer Immunol Res (2014) 2(2):91–8. doi:10.1158/2326-
6066.CIR-13-0216 
84. Lim SD, Kiszkiss DF, Jacobson RR, Choi YS, Good RA. Thymus-dependent 
lymphocytes of peripheral blood in leprosy patients. Infect Immun (1974) 
9(2):394–9. 
85. Rao TD, Rao PR. Enhanced cell-mediated immune responses in erythema 
nodosum leprosum reactions of leprosy. Int J Lepr Other Mycobact Dis (1987) 
55(1):36–41. 
86. Bach MA, Chatenoud L, Wallach D, Phan Dinh Tuy F, Cottenot F. Studies 
on T  cell subsets and functions in leprosy. Clin Exp Immunol (1981) 
44(3):491–500. 
87. Wallach D, Cottenot F, Bach MA. Imbalances in T  cell subpopulations in 
lepromatous leprosy. Int J Lepr Other Mycobact Dis (1982) 50(3):282–90. 
88. Mshana RN, Haregewoin A, Harboe M, Belehu A. Thymus dependent lym-
phocytes in leprosy. I. T lymphocyte subpopulations defined by monoclonal 
antibodies. Int J Lepr Other Mycobact Dis (1982) 50(3):291–6. 
89. Narayanan RB, Laal S, Sharma AK, Bhutani LK, Nath I. Differences in 
predominant T  cell phenotypes and distribution pattern in reactional 
lesions of tuberculoid and lepromatous leprosy. Clin Exp Immunol (1984) 
55(3):623–8. 
90. Mshana RN, Haregewoin A, Belehu A. Thymus-dependent lymphocytes in 
leprosy. II. Effect of chemotherapy on T-lymphocyte subpopulations. J Clin 
Immunol (1982) 2(2):69–74. doi:10.1007/BF00916889 
91. Wallach D, Flageul B, Cottenot F, Bach MA. Patients with erythema nodo-
sum leprosum lack T-suppressor cells. Arch Dermatol (1985) 121(11):1379. 
doi:10.1001/archderm.1985.01660110027002 
92. Hussain T, Kulshreshtha KK, Yadav VS, Katoch K. CD4+, CD8+, CD3+ 
cell counts and CD4+/CD8+ ratio among patients with mycobacterial 
diseases (leprosy, tuberculosis), HIV infections, and normal healthy adults: a 
comparative analysis of studies in different regions of India. J Immunoassay 
Immunochem (2015) 36(4):420–43. doi:10.1080/15321819.2014.978082 
93. Sakane T, Steinberg AD, Green I. Studies of immune functions of patients 
with systemic lupus erythematosus. I. Dysfunction of suppressor T-cell 
activity related to impaired generation of, rather than response to, 
suppressor cells. Arthritis Rheum (1978) 21(6):657–64. doi:10.1002/art. 
1780210608 
94. Laal S, Bhutani LK, Nath I. Natural emergence of antigen-reactive T  cells 
in lepromatous leprosy patients during erythema nodosum leprosum. Infect 
Immun (1985) 50(3):887–92. 
95. Bullock WE. Leprosy: a model of immunological perturbation in chronic 
infection. J Infect Dis (1978) 137(3):341–54. doi:10.1093/infdis/137.3.341 
96. Rea TH, Bakke AC, Parker JW, Modlin RL, Horwitz DA. Peripheral blood 
T  lymphocyte subsets in leprosy. Int J Lepr Other Mycobact Dis (1984) 
52(3):311–7. 
97. Modlin RL, Gebhard JF, Taylor CR, Rea TH. In situ characterization of 
T lymphocyte subsets in the reactional states of leprosy. Clin Exp Immunol 
(1983) 53(1):17–24. 
98. Modlin RL, Hofman FM, Taylor CR, Rea TH. T lymphocyte subsets in the 
skin lesions of patients with leprosy. J Am Acad Dermatol (1983) 8(2):182–9. 
doi:10.1016/S0190-9622(83)70021-6 
99. Modlin RL, Bakke AC, Vaccaro SA, Horwitz DA, Taylor CR, Rea TH. 
Tissue and blood T-lymphocyte subpopulations in erythema nodosum 
leprosum. Arch Dermatol (1985) 121(2):216–9. doi:10.1001/archderm. 
121.2.216 
100. Modlin RL, Mehra V, Jordan R, Bloom BR, Rea TH. In situ and in  vitro 
characterization of the cellular immune response in erythema nodosum 
leprosum. J Immunol (1986) 136(3):883–6. 
101. Shen JY, Hofman FM, Gunter JR, Modlin RL, Rea TH. In situ identification of 
activated Ta1+ T lymphocytes in human leprosy skin lesions. Int J Lepr Other 
Mycobact Dis (1987) 55(3):494–8. 
102. Rea TH, Modlin RL. Immunopathology of leprosy skin lesions. Semin 
Dermatol (1991) 10(3):188–93. 
103. Mahaisavariya P, Kulthanan K, Khemngern S, Pinkaew S. Lesional T-cell 
subset in leprosy and leprosy reaction. Int J Dermatol (1999) 38(5):345–7. 
doi:10.1046/j.1365-4362.1999.00621.x 
104. Fehervari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest 
(2004) 114(9):1209–17. doi:10.1172/JCI23395 
105. Saini C, Prasad HK, Rani R, Murtaza A, Misra N, Narayan NP, et al. Lsr 2 of 
Mycobacterium leprae and its synthetic peptides elicit restitution of in vitro 
T cell responses in erythema nodosum leprosum and reversal reactions in 
lepromatous leprosy patients. Clin Vaccine Immunol (2013) 20(5):673–82. 
doi:10.1128/CVI.00762-12 
106. Saini C, Ramesh V, Nath I. CD4+ Th17  cells discriminate clinical types 
and constitute a third subset of non Th1, Non Th2 T  cells in human 
leprosy. PLoS Negl Trop Dis (2013) 7(7):e2338. doi:10.1371/journal.pntd. 
0002338 
107. Attia EA, Abdallah M, Saad AA, Afifi A, El Tabbakh A, El-Shennawy 
D, et  al. Circulating CD4+ CD25 high FoxP3+ T  cells vary in differ-
ent clinical forms of leprosy. Int J Dermatol (2010) 49(10):1152–8. 
doi:10.1111/j.1365-4632.2010.04535.x 
108. Boer MC, Joosten SA, Ottenhoff TH. Regulatory T-cells at the interface 
between human host and pathogens in infectious diseases and vaccination. 
Front Immunol (2015) 6:217. doi:10.3389/fimmu.2015.00217 
109. Abdallah M, Attia EA, Saad AA, El-Khateeb EA, Lotfi RA, Abdallah M, et al. 
Serum Th1/Th2 and macrophage lineage cytokines in leprosy; correlation 
with circulating CD4(+) CD25(high) FoxP3(+) T-regs cells. Exp Dermatol 
(2014) 23(10):742–7. doi:10.1111/exd.12529 
110. Attia EA, Abdallah M, El-Khateeb E, Saad AA, Lotfi RA, Abdallah M, 
et  al. Serum Th17 cytokines in leprosy: correlation with circulating 
CD4(+) CD25 (high)FoxP3 (+) T-regs cells, as well as down regulatory 
cytokines. Arch Dermatol Res (2014) 306(9):793–801. doi:10.1007/s00403- 
014-1486-2 
111. Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore 
A, et  al. Monitoring regulatory T  cells in clinical samples: consensus on 
an essential marker set and gating strategy for regulatory T  cell analysis 
by flow cytometry. Cancer Immunol Immunother (2015) 64(10):1271–86. 
doi:10.1007/s00262-015-1729-x 
38
Polycarpou et al. Immunology of Erythema Nodosum Leprosum
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 233
112. Brusko T, Wasserfall C, McGrail K, Schatz R, Viener HL, Schatz D, et al. No 
alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. 
Diabetes (2007) 56(3):604–12. doi:10.2337/db06-1248 
113. Saini C, Siddiqui A, Ramesh V, Nath I. Leprosy reactions show increased 
Th17 cell activity and reduced FOXP3+ Tregs with concomitant decrease in 
TGF-beta and increase in IL-6. PLoS Negl Trop Dis (2016) 10(4):e0004592. 
doi:10.1371/journal.pntd.0004592 
114. Ye ZJ, Zhou Q, Du RH, Li X, Huang B, Shi HZ. Imbalance of Th17 cells and 
regulatory T  cells in tuberculous pleural effusion. Clin Vaccine Immunol 
(2011) 18(10):1608–15. doi:10.1128/CVI.05214-11 
115. Haslett PA, Roche P, Butlin CR, Macdonald M, Shrestha N, Manandhar R, 
et al. Effective treatment of erythema nodosum leprosum with thalidomide 
is associated with immune stimulation. J Infect Dis (2005) 192(12):2045–53. 
doi:10.1086/498216 
116. Massone C, Nunzi E, Ribeiro-Rodrigues R, Talhari C, Talhari S, Schettini AP, 
et al. T regulatory cells and plasmocytoid dentritic cells in hansen disease: 
a new insight into pathogenesis? Am J Dermatopathol (2010) 32(3):251–6. 
doi:10.1097/DAD.0b013e3181b7fc56 
117. Miyao T, Floess S, Setoguchi R, Luche H, Fehling HJ, Waldmann H, et al. 
Plasticity of Foxp3(+) T  cells reflects promiscuous Foxp3 expression in 
conventional T cells but not reprogramming of regulatory T cells. Immunity 
(2012) 36(2):262–75. doi:10.1016/j.immuni.2011.12.012 
118. Rea TH, Levan NE. Variations in dinitrochlorobenzene responsivity in 
untreated leprosy: evidence of a beneficial role for anergy. Int J Lepr Other 
Mycobact Dis (1980) 48(2):120–5. 
119. Anders EM, McAdam KP, Anders RF. Cell-mediated immunity in amyloido-
sis secondary to lepromatous leprosy. Clin Exp Immunol (1977) 27(1):111–7. 
120. Dubey GK, Joglekar VK, Hardas UD, Chaubey BS. A study of cell mediated 
immunity in leprosy. Lepr India (1981) 53(2):197–203. 
121. Bach MA, Hoffenbach A, Lagrange PH, Wallach D, Cottenot F. Mechanisms 
of T-cell unresponsiveness in leprosy. Ann Immunol (1983) 134D(1):75–84. 
122. Sasiain MC, Ruibal Ares B, Balina LM, Valdez R, Bachmann AE. ConA-
induced suppressor cells in lepromatous leprosy patients during and 
after erythema nodosum leprosum. Int J Lepr Other Mycobact Dis (1983) 
51(3):321–7. 
123. Rao TD, Rao PR. Tr, T mu and B lymphocytes in erythema nodosum lepro-
sum reactions of leprosy. Indian J Lepr (1986) 58(4):601–8. 
124. Bottasso O, Puig N, Amerio N, Morini JC. [Study of T lymphocyte subpop-
ulations in patients with leprosy, using incubation with theophylline]. Med 
Cutan Ibero Lat Am (1988) 16(5):397–401. 
125. Rasheed FN, Locniskar M, McCloskey DJ, Hasan RS, Chiang TJ, Rose P, 
et al. Serum lymphocytotoxic activity in leprosy. Clin Exp Immunol (1989) 
76(3):391–7. 
126. Sasiain MD, de la Barrera S, Valdez R, Balina LM. Reduced suppressor cell 
response to Mycobacterium leprae in lepromatous leprosy. Infect Immun 
(1989) 57(3):951–6. 
127. Bhoopat L, Scollard DM, Theetranont C, Chiewchanvit S, Nelson DL, Utaipat 
U. Studies of human leprosy lesions in situ using suction-induced blisters: cell 
changes with IgM antibody to PGL-1 and interleukin-2 receptor in clinical 
subgroups of erythema nodosum leprosum. Asian Pac J Allergy Immunol 
(1991) 9(2):107–19. 
128. Foss NT, de Oliveira EB, Silva CL. Correlation between TNF production, 
increase of plasma C-reactive protein level and suppression of T lymphocyte 
response to concanavalin A during erythema nodosum leprosum. Int J Lepr 
Other Mycobact Dis (1993) 61(2):218–26. 
129. Santos DO, Suffys PN, Moreira AL, Bonifacio K, Salgado JL, Esquenazi D, 
et  al. Evaluation of chemiluminescence, procoagulant activity and antigen 
presentation by monocytes from lepromatous leprosy patients with or 
without reactional episodes. Lepr Rev (1994) 65(2):88–99. 
130. de la Barrera S, Fink S, Finiasz M, Minnucci F, Valdez R, Balina LM, et al. Lack 
of cytotoxic activity against Mycobacterium leprae 65-kD heat shock protein 
(hsp) in multibacillary leprosy patients. Clin Exp Immunol (1995) 99(1):90–7. 
doi:10.1111/j.1365-2249.1995.tb03477.x 
131. Vieira LM, Sampaio EP, Nery JA, Duppre NC, Albuquerque EC, Scheinberg 
MA, et  al. Immunological status of ENL (erythema nodosum lepro-
sum) patients: its relationship to bacterial load and levels of circulating 
IL-2R. Rev Inst Med Trop Sao Paulo (1996) 38(2):103–11. doi:10.1590/
S0036-46651996000200004 
132. Tadesse A, Taye E, Sandoval F, Shannon EJ. Thalidomide does not modify 
the ability of cells in leprosy patients to incorporate [3H]-thymidine when 
incubated with M. leprae antigens. Lepr Rev (2003) 74(3):206–14. 
133. Mohanty KK, Joshi B, Katoch K, Sengupta U. Leprosy reactions: humoral 
and cellular immune responses to M. leprae, 65kDa, 28kDa, and 18 kDa 
antigens. Int J Lepr Other Mycobact Dis (2004) 72(2):149–58. doi:10.1489/ 
1544-581X(2004)072<0149:LRHACI>2.0.CO;2 
134. Villahermosa LG, Fajardo TT Jr, Abalos RM, Balagon MV, Tan EV, Cellona 
RV, et  al. A randomized, double-blind, double-dummy, controlled dose 
comparison of thalidomide for treatment of erythema nodosum leprosum. 
Am J Trop Med Hyg (2005) 72(5):518–26. 
135. Rada E, Aranzazu N, Rodriguez V, Borges R, Convit J. [Serological and 
cellular reactivity to mycobacterial proteins in Hansen’s disease]. Invest Clin 
(2010) 51(3):325–40. 
136. Saini C, Prasad HK, Rani R, Murtaza A, Misra N, Shanker Narayan NP, et al. 
Lsr2 of Mycobacterium leprae and its synthetic peptides elicit restitution of 
T cell responses in erythema nodosum leprosum and reversal reactions in 
patients with lepromatous leprosy. Clin Vaccine Immunol (2013) 20(5):673–
82. doi:10.1128/CVI.00762-12 
137. Parente JN, Talhari C, Schettini AP, Massone C. T regulatory cells (TREG)
(TCD4+CD25+FOXP3+) distribution in the different clinical forms of lep-
rosy and reactional states. An Bras Dermatol (2015) 90(1):41–7. doi:10.1590/
abd1806-4841.20153311 
138. Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis 
factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp 
Immunol (1991) 84(1):103–8. 
139. Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, et al. The 
influence of thalidomide on the clinical and immunologic manifestation of 
erythema nodosum leprosum. J Infect Dis (1993) 168(2):408–14. doi:10.1093/
infdis/168.2.408 
140. Parida SK, Grau GE, Zaheer SA, Mukherjee R. Serum tumor necrosis factor 
and interleukin 1 in leprosy and during lepra reactions. Clin Immunol 
Immunopathol (1992) 63(1):23–7. doi:10.1016/0090-1229(92)90088-6 
141. Memon RA, Kifayet A, Shahid F, Lateef A, Chiang J, Hussain R. Low serum 
HDL-cholesterol is associated with raised tumor necrosis factor-alpha during 
ENL reactions. Int J Lepr Other Mycobact Dis (1997) 65(1):1–11. 
142. Partida-Sanchez S, Favila-Castillo L, Pedraza-Sanchez S, Gomez-Melgar 
M, Saul A, Estrada-Parra S, et al. IgG antibody subclasses, tumor necrosis 
factor and IFN-gamma levels in patients with type II lepra reaction on 
thalidomide treatment. Int Arch Allergy Immunol (1998) 116(1):60–6. 
doi:10.1159/000023926 
143. Iyer A, Hatta M, Usman R, Luiten S, Oskam L, Faber W, et  al. Serum 
levels of interferon-gamma, tumour necrosis factor-alpha, soluble inter-
leukin-6R and soluble cell activation markers for monitoring response to 
treatment of leprosy reactions. Clin Exp Immunol (2007) 150(2):210–6. 
doi:10.1111/j.1365-2249.2007.03485.x 
144. Madan NK, Agarwal K, Chander R. Serum cytokine profile in leprosy 
and its correlation with clinico-histopathological profile. Lepr Rev (2011) 
82(4):371–82. 
145. Rodrigues LS, Hacker MA, Illarramendi X, Pinheiro MF, Nery JA, 
Sarno EN, et  al. Circulating levels of insulin-like growth factor-I (IGF-I) 
correlate with disease status in leprosy. BMC Infect Dis (2011) 11:339. 
doi:10.1186/1471-2334-11-339 
146. Bhattacharya SN, Chattopadhaya D, Saha K. Tumor necrosis factor: status 
in reactions in leprosy before and after treatment. Int J Dermatol (1993) 
32(6):436–9. doi:10.1111/j.1365-4362.1993.tb02816.x 
147. Sampaio EP, Moraes MO, Nery JA, Santos AR, Matos HC, Sarno EN. 
Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha 
(TNF-alpha) production in lepromatous leprosy patients with erythema 
nodosum leprosum (ENL). Clin Exp Immunol (1998) 111(2):300–8. 
doi:10.1046/j.1365-2249.1998.00510.x 
148. Moubasher AD, Kamel NA, Zedan H, Raheem DD. Cytokines in leprosy, 
I. Serum cytokine profile in leprosy. Int J Dermatol (1998) 37(10):733–40. 
doi:10.1046/j.1365-4362.1998.00381.x 
149. Jadhav R, Suneetha L, Kamble R, Shinde V, Devi K, Chaduvula MV, et al. 
Analysis of antibody and cytokine markers for leprosy nerve damage and 
reactions in the INFIR cohort in India. PLoS Negl Trop Dis (2011) 5(3):e977. 
doi:10.1371/journal.pntd.0000977 
39
Polycarpou et al. Immunology of Erythema Nodosum Leprosum
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 233
150. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged 
treatment with recombinant interferon gamma induces erythema nodosum 
leprosum in lepromatous leprosy patients. J Exp Med (1992) 175(6):1729–37. 
doi:10.1084/jem.175.6.1729 
151. Stefani MM, Guerra JG, Sousa AL, Costa MB, Oliveira ML, Martelli CT, 
et  al. Potential plasma markers of Type 1 and Type 2 leprosy reactions: 
a preliminary report. BMC Infect Dis (2009) 9:75. doi:10.1186/1471- 
2334-9-75 
152. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, 
et  al. Randomised comparison of thalidomide versus placebo in toxic 
epidermal necrolysis. Lancet (1998) 352(9140):1586–9. doi:10.1016/
S0140-6736(98)02197-7 
153. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, 
et al. Thalidomide for the treatment of oral aphthous ulcers in patients with 
human immunodeficiency virus infection. National Institute of Allergy 
and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med (1997) 
336(21):1487–93. doi:10.1056/NEJM199705223362103 
154. Haslett PA, Hanekom WA, Muller G, Kaplan G. Thalidomide and a thalido-
mide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect 
Dis (2003) 187(6):946–55. doi:10.1086/368126 
155. Barnes PF, Chatterjee D, Brennan PJ, Rea TH, Modlin RL. Tumor necrosis 
factor production in patients with leprosy. Infect Immun (1992) 60(4): 
1441–6. 
156. Santos DO, Suffys PN, Bonifacio K, Marques MA, Sarno EN. In vitro 
tumor necrosis factor production by mononuclear cells from lepromatous 
leprosy patients and from patients with erythema nodosum leprosum. 
Clin Immunol Immunopathol (1993) 67(3 Pt 1):199–203. doi:10.1006/clin. 
1993.1065 
157. Sampaio EP, Oliveira RB, Warwick-Davies J, Neto RB, Griffin GE, Shattock 
RJ. T cell-monocyte contact enhances tumor necrosis factor-alpha produc-
tion in response to Mycobacterium leprae. J Infect Dis (2000) 182(5):1463–72. 
doi:10.1086/315902 
158. Faber WR, Jensema AJ, Goldschmidt WF. Treatment of recurrent erythema 
nodosum leprosum with infliximab. N Engl J Med (2006) 355(7):739. 
doi:10.1056/NEJMc052955 
159. Ramien ML, Wong A, Keystone JS. Severe refractory erythema nodosum 
leprosum successfully treated with the tumor necrosis factor inhibitor 
etanercept. Clin Infect Dis (2011) 52(5):e133–5. doi:10.1093/cid/ciq213 
160. Chowdhry S, Shukla A, D’Souza P, Dhali T, Jaiswal P. Treatment of severe 
refractory erythema nodosum leprosum with tumor necrosis factor 
inhibitor etanercept. Int J Mycobacteriol (2016) 5(2):223–5. doi:10.1016/ 
j.ijmyco.2016.02.002 
161. Moraes MO, Sarno EN, Almeida AS, Saraiva BC, Nery JA, Martins RC, et al. 
Cytokine mRNA expression in leprosy: a possible role for interferon-gamma 
and interleukin-12 in reactions (RR and ENL). Scand J Immunol (1999) 
50(5):541–9. doi:10.1046/j.1365-3083.1999.00622.x 
162. Nath I, Vemuri N, Reddi AL, Bharadwaj M, Brooks P, Colston MJ, et  al. 
Dysregulation of IL-4 expression in lepromatous leprosy patients with 
and without erythema nodosum leprosum. Lepr Rev (2000) 71(Suppl): 
S130–7. 
163. Nath I, Vemuri N, Reddi AL, Jain S, Brooks P, Colston MJ, et al. The effect 
of antigen presenting cells on the cytokine profiles of stable and reactional 
lepromatous leprosy patients. Immunol Lett (2000) 75(1):69–76. doi:10.1016/
S0165-2478(00)00271-6 
164. Moraes MO, Sarno EN, Teles RM, Almeida AS, Saraiva BC, Nery JA, et al. 
Anti-inflammatory drugs block cytokine mRNA accumulation in the skin 
and improve the clinical condition of reactional leprosy patients. J Invest 
Dermatol (2000) 115(6):935–41. doi:10.1046/j.1523-1747.2000.00158.x 
165. Moubasher AD, Kamel NA, Zedan H, Raheem DD. Cytokines in leprosy, 
II. Effect of treatment on serum cytokines in leprosy. Int J Dermatol (1998) 
37(10):741–6. doi:10.1046/j.1365-4362.1998.00381.x 
166. Sallam MA, Attia EA, Soliman MS. Assessment of serum level of interleu-
kin-1b and interleukin-12 in leprosy: impact of previous bacillus calmitte 
guerin vaccination. Arch Dermatol Res (2014) 306(2):189–95. doi:10.1007/
s00403-013-1411-0 
167. Berrington WR, Kunwar CB, Neupane K, van den Eeden SJ, Vary JC Jr, 
Peterson GJ, et al. Differential dermal expression of CCL17 and CCL18 in 
tuberculoid and lepromatous leprosy. PLoS Negl Trop Dis (2014) 8(11):e3263. 
doi:10.1371/journal.pntd.0003263 
168. Filley E, Andreoli A, Steele J, Waters M, Wagner D, Nelson D, et  al.  
A transient rise in agalactosyl IgG correlating with free interleukin 2 recep-
tors, during episodes of erythema nodosum leprosum. Clin Exp Immunol 
(1989) 76(3):343–7. 
169. Belgaumkar VA, Gokhale NR, Mahajan PM, Bharadwaj R, Pandit DP, 
Deshpande S. Circulating cytokine profiles in leprosy patients. Lepr Rev 
(2007) 78(3):223–30. 
170. Sousa AL, Fava VM, Sampaio LH, Martelli CM, Costa MB, Mira MT, et al. 
Genetic and immunological evidence implicates interleukin 6 as a suscep-
tibility gene for leprosy type 2 reaction. J Infect Dis (2012) 205(9):1417–24. 
doi:10.1093/infdis/jis208 
171. Abdallah M, Emam H, Attia E, Hussein J, Mohamed N. Estimation of serum 
level of interleukin-17 and interleukin-4 in leprosy, towards more under-
standing of leprosy immunopathogenesis. Indian J Dermatol Venereol Leprol 
(2013) 79(6):772–6. doi:10.4103/0378-6323.120723 
172. Sehgal VN, Bhattacharya SN, Shah Y, Sharma VK, Gupta CK. Soluble inter-
leukin-2 receptors: levels in leprosy, and during and after type 1 (lepra) and 
type 2 (ENL) reactions. Lepr Rev (1991) 62(3):262–8. 
173. Sullivan L, Sano S, Pirmez C, Salgame P, Mueller C, Hofman F, et  al. 
Expression of adhesion molecules in leprosy lesions. Infect Immun (1991) 
59(11):4154–60. 
174. Goulart IM, Mineo JR, Foss NT. Production of transforming growth 
factor-beta 1 (TGF-beta1) by blood monocytes from patients with dif-
ferent clinical forms of leprosy. Clin Exp Immunol (2000) 122(3):330–4. 
doi:10.1046/j.1365-2249.2000.01376.x 
175. Motta AC, Furini RB, Simao JC, Ferreira MA, Komesu MC, Foss NT. 
The recurrence of leprosy reactional episodes could be associated with 
oral chronic infections and expression of serum IL-1, TNF-alpha, IL-6, 
IFN-gamma and IL-10. Braz Dent J (2010) 21(2):158–64. doi:10.1590/
S0103-64402010000200012 
176. Teles RM, Teles RB, Amadeu TP, Moura DF, Mendonca-Lima L, Ferreira H, 
et al. High matrix metalloproteinase production correlates with immune acti-
vation and leukocyte migration in leprosy reactional lesions. Infect Immun 
(2010) 78(3):1012–21. doi:10.1128/IAI.00896-09 
177. Chaitanya S, Lavania M, Turankar RP, Karri SR, Sengupta U. Increased serum 
circulatory levels of interleukin 17F in type 1 reactions of leprosy. J Clin 
Immunol (2012) 32(6):1415–20. doi:10.1007/s10875-012-9747-3 
178. Lockwood DN, Nicholls P, Smith WC, Das L, Barkataki P, van Brakel W, 
et  al. Comparing the clinical and histological diagnosis of leprosy and 
leprosy reactions in the INFIR cohort of Indian patients with multibacillary 
leprosy. PLoS Negl Trop Dis (2012) 6(6):e1702. doi:10.1371/journal.pntd. 
0001702 
179. Martiniuk F, Giovinazzo J, Tan AU, Shahidullah R, Haslett P, Kaplan G, et al. 
Lessons of leprosy: the emergence of TH17 cytokines during type II reac-
tions (ENL) is teaching us about T-cell plasticity. J Drugs Dermatol (2012) 
11(5):626–30. 
180. Reichlin M, Pranis RA, Gelber RH, Rees RJ, Taverne J, Turk JL. Correlation 
of euglobulin immunoglobulin G levels with erythema nodosum leprosum 
in lepromatous leprosy. Clin Immunol Immunopathol (1977) 8(2):335–44. 
doi:10.1016/0090-1229(77)90123-4 
181. Humphres RC, Gelber RH, Krahenbuhl JL. Suppressed natural killer cell 
activity during episodes of erythema nodosum leprosum in lepromatous 
leprosy. Clin Exp Immunol (1982) 49(3):500–8. 
182. Rea TH, Yoshida T. Serum macrophage migration inhibition activity in 
patients with leprosy. J Invest Dermatol (1982) 79(5):336–9. doi:10.1111/1523-
1747.ep12500088 
183. Miller RA, Harnisch JP, Buchanan TM. Antibodies to mycobacterial arabi-
nomannan in leprosy: correlation with reactional states and variation during 
treatment. Int J Lepr Other Mycobact Dis (1984) 52(2):133–9. 
184. Schwerer B, Meeker HC, Sersen G, Levis WR. IgM antibodies against 
phenolic glycolipid I from Mycobacterium leprae in leprosy sera: relationship 
to bacterial index and erythema nodosum leprosum. Acta Leprol (1984) 
2(2–4):394–402. 
185. Blavy G, Thiam D, Ndoye B, Diakhate L, Millan J. [HLA and leprosy in Dakar: 
distribution of histocompatibility antigens in leprous patients and their 
relationship to ENL reactions]. Acta Leprol (1986) 4(1):93–9. 
186. Levis WR, Meeker HC, Schuller-Levis G, Sersen E, Schwerer B. IgM and IgG 
antibodies to phenolic glycolipid I from Mycobacterium leprae in leprosy: 
insight into patient monitoring, erythema nodosum leprosum, and bacillary 
40
Polycarpou et al. Immunology of Erythema Nodosum Leprosum
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 233
persistence. J Invest Dermatol (1986) 86(5):529–34. doi:10.1111/1523-1747.
ep12354963 
187. Levis WR, Meeker HC, Schuller-Levis G, Sersen E, Brennan PJ, Fried P. 
Mycobacterial carbohydrate antigens for serological testing of patients with 
leprosy. J Infect Dis (1987) 156(5):763–9. doi:10.1093/infdis/156.5.763 
188. Sehgal VN, Bhattacharya SN, Shah Y, Rao YN, Gupta CK. Lymphocyte 
adenosine deaminase activity (L-ADA) in leprosy, during and after 
treatment of reactions. Clin Exp Dermatol (1992) 17(1):20–3. doi:10.1111/ 
j.1365-2230.1992.tb02526.x 
189. Singh S, Jenner PJ, Narayan NP, Ramu G, Colston MJ, Prasad HK, et  al. 
Critical residues of the Mycobacterium leprae LSR recombinant protein dis-
criminate clinical activity in erythema nodosum leprosum reactions. Infect 
Immun (1994) 62(12):5702–5. 
190. Kifayet A, Hussain R. Selective decrease of M. leprae-specific IgG1 and IgG3 
antibodies in leprosy patients associated with ENL. Int J Lepr Other Mycobact 
Dis (1996) 64(2):105–14. 
191. Kifayet A, Shahid F, Lucas S, Hussain R. Erythema nodosum leprosum is 
associated with up-regulation of polyclonal IgG1 antibody synthesis. Clin Exp 
Immunol (1996) 106(3):447–53. doi:10.1046/j.1365-2249.1996.d01-860.x 
192. Beuria MK, Parkash O, Joshi B, Mohanty KK, Katoch K, Sengupta U. 
Levels of IgG subclasses in active and inactive cases in the disease spectrum 
of leprosy. Int Arch Allergy Immunol (1998) 115(1):61–6. doi:10.1159/ 
000023831 
193. Freire BF, Ferraz AA, Nakayama E, Ura S, Queluz TT. Anti-neutrophil 
cytoplasmic antibodies (ANCA) in the clinical forms of leprosy. Int J Lepr 
Other Mycobact Dis (1998) 66(4):475–82. 
194. Stefani MM, Martelli CM, Morais-Neto OL, Martelli P, Costa MB, de Andrade 
AL. Assessment of anti-PGL-I as a prognostic marker of leprosy reaction. Int 
J Lepr Other Mycobact Dis (1998) 66(3):356–64. 
195. Beuria MK, Mohanty KK, Katoch K, Sengupta U. Determination of circulat-
ing IgG subclasses against lipoarabinomannan in the leprosy spectrum and 
reactions. Int J Lepr Other Mycobact Dis (1999) 67(4):422–8. 
196. Hamerlinck FF, Klatser PR, Walsh DS, Bos JD, Walsh GP, Faber WR. 
Serum neopterin as a marker for reactional states in leprosy. FEMS 
Immunol Med Microbiol (1999) 24(4):405–9. doi:10.1111/j.1574-695X.1999. 
tb01312.x 
197. Mahaisavariya P, Jiamton S, Manonukul J, Khemngern S. Mast cells 
in leprosy and leprosy reaction. Int J Dermatol (2000) 39(4):274–7. 
doi:10.1046/j.1365-4362.2000.00908.x 
198. Schon T, Leekassa R, Gebre N, Sundqvist T, Bizuneh E, Britton S. High dose 
prednisolone treatment of leprosy patients undergoing reactions is associ-
ated with a rapid decrease in urinary nitric oxide metabolites and clinical 
improvement. Lepr Rev (2000) 71(3):355–62. 
199. Antunes SL, Liang Y, Neri JA, Sarno EN, Haak-Frendscho M, Johansson O. 
Mast cell subsets and neuropeptides in leprosy reactions. Arq Neuropsiquiatr 
(2003) 61(2A):208–19. doi:10.1590/S0004-282X2003000200010 
200. Rada E, Marzal M, Aranzazu N, Convit J. [Increase in nitric oxide concen-
trations in serum and mononuclear cell cultures from patients with Type II 
reaction state of Hansen’s disease]. Invest Clin (2003) 44(2):129–36. 
201. Sunderkotter CH, Tomimori-Yamashita J, Nix V, Maeda SM, Sindrilaru 
A, Mariano M, et  al. High expression of myeloid-related proteins 8 
and 14 characterizes an inflammatorily active but ineffective response 
of macrophages during leprosy. Immunology (2004) 111(4):472–80. 
doi:10.1111/j.0019-2805.2004.01836.x 
202. Nigam PK, Srivastava P, Patra PK. Serum adenosine deaminase levels in 
reactional and non-reactional leprosy. Indian J Dermatol Venereol Leprol 
(2005) 71(1):20–2. doi:10.4103/0378-6323.13780 
203. Mohanty KK, Gupta M, Girdhar BK, Girdhar A, Chakma JK, Sengupta U. 
Increased level of urinary nitric oxide metabolites in leprosy patients during 
type 2 reactions and decreased after antireactional therapy. Lepr Rev (2007) 
78(4):386–90. 
204. Santos DO, Castro HC, Bourguignon SC, Bastos OM, Rodrigues CR, Van 
Heuverswyn H, et al. Expression of B7-1 costimulatory molecules in patients 
with multibacillary leprosy and reactional states. Clin Exp Dermatol (2007) 
32(1):75–80. doi:10.1111/j.1365-2230.2006.02291.x 
205. Silva EA, Iyer A, Ura S, Lauris JR, Naafs B, Das PK, et al. Utility of measuring 
serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in 
monitoring leprosy patients during multi-drug treatment and reactions. 
Trop Med Int Health (2007) 12(12):1450–8. doi:10.1111/j.1365-3156.2007. 
01951.x 
206. Brito Mde F, Ximenes RA, Gallo ME, Buhrer-Sekula S. Association between 
leprosy reactions after treatment and bacterial load evaluated using 
anti PGL-I serology and bacilloscopy. Rev Soc Bras Med Trop (2008) 41 
(Suppl 2):67–72. 
207. Iyer A, van Eijk M, Silva E, Hatta M, Faber W, Aerts JM, et  al. Increased 
chitotriosidase activity in serum of leprosy patients: association with bac-
illary leprosy. Clin Immunol (2009) 131(3):501–9. doi:10.1016/j.clim.2009. 
02.003 
208. Singh I, Yadav AR, Mohanty KK, Katoch K, Bisht D, Sharma P, et  al. 
Molecular mimicry between HSP 65 of Mycobacterium leprae and cytokera-
tin 10 of the host keratin; role in pathogenesis of leprosy. Cell Immunol (2012) 
278(1–2):63–75. doi:10.1016/j.cellimm.2012.06.011 
209. Mandal D, Reja AH, Biswas N, Bhattacharyya P, Patra PK, Bhattacharya B. 
Vitamin D receptor expression levels determine the severity and complexity 
of disease progression among leprosy reaction patients. New Microbes New 
Infect (2015) 6:35–9. doi:10.1016/j.nmni.2015.04.001 
210. Berrington WR, Macdonald M, Khadge S, Sapkota BR, Janer M, Hagge DA, 
et  al. Common polymorphisms in the NOD2 gene region are associated 
with leprosy and its reactive states. J Infect Dis (2010) 201(9):1422–35. 
doi:10.1086/651559 
211. Teixeira MA, Silva NL, Ramos Ade L, Hatagima A, Magalhaes V. [NRAMP1 
gene polymorphisms in individuals with leprosy reactions attended at two 
reference centers in Recife, northeastern Brazil]. Rev Soc Bras Med Trop 
(2010) 43(3):281–6. doi:10.1590/S0037-86822010000300014 
212. de Sales Marques C, Brito-de-Souza VN, Albuquerque Guerreiro LT, Martins 
JH, Amaral EP, Cardoso CC, et al. Toll-like receptor 1 (TLR1) N248S single 
nucleotide polymorphism is associated with leprosy risk and regulates 
immune activation during mycobacterial infection. J Infect Dis (2013) 
208(1):120–9. doi:10.1093/infdis/jit133 
213. Schuring RP, Hamann L, Faber WR, Pahan D, Richardus JH, Schumann 
RR, et  al. Polymorphism N248S in the human toll-like receptor 1 gene is 
related to leprosy and leprosy reactions. J Infect Dis (2009) 199(12):1816–9. 
doi:10.1086/599121 
214. Scotland RS, Stables MJ, Madalli S, Watson P, Gilroy DW. Sex differences in 
resident immune cell phenotype underlie more efficient acute inflammatory 
responses in female mice. Blood (2011) 118(22):5918–27. doi:10.1182/
blood-2011-03-340281 
215. Tan Trao V, Huong PL, Thuan AT, Long HT, Trach DD, Wright EP. Responses 
to Mycobacterium leprae by lymphocytes from new and old leprosy 
patients: role of exogenous lymphokines. Ann Inst Pasteur Immunol (1988) 
139(2):121–33. doi:10.1016/0769-2625(88)90034-7 
216. Beyrau M, Bodkin JV, Nourshargh S. Neutrophil heterogeneity in health 
and disease: a revitalized avenue in inflammation and immunity. Open Biol 
(2012) 2(11):120134. doi:10.1098/rsob.120134 
217. Fatima N, Faisal SM, Zubair S, Ajmal M, Siddiqui SS, Moin S, et al. Role of 
pro-inflammatory cytokines and biochemical markers in the pathogenesis 
of type 1 diabetes: correlation with age and glycemic condition in diabetic 
human subjects. PLoS One (2016) 11(8):e0161548. doi:10.1371/journal.
pone.0161548 
218. Anderson R, Gatner EM, van Rensburg CE, Grabow G, Imkamp FM, 
Kok SK, et  al. In vitro and in  vivo effects of dapsone on neutrophil and 
lymphocyte functions in normal individuals and patients with lepromatous 
leprosy. Antimicrob Agents Chemother (1981) 19(4):495–503. doi:10.1128/
AAC.19.4.495 
219. Anderson R, Gatner EM. Changes in neutrophil motility accompanying 
dapsone and rifampicin therapy. Lepr Rev (1981) 52(1):19–22. 
220. Anderson R. Enhancement by clofazimine and inhibition by dapsone of 
production of prostaglandin E2 by human polymorphonuclear leukocytes 
in  vitro. Antimicrob Agents Chemother (1985) 27(2):257–62. doi:10.1128/
AAC.27.2.257 
221. Das PK, Klatser PR, Pondman KW, Huikeshoven H, Landheer JE, Leiker 
DL, et  al. Dapsone and anti-dapsone antibody in circulating immune 
complexes in leprosy patients. Lancet (1980) 1(8181):1309–11. doi:10.1016/
S0140-6736(80)91772-9 
222. Trao VT, Huong PL, Thuan AT, Anh DD, Trach DD, Rook GA, et al. Changes 
in cellular response to mycobacterial antigens and cytokine production 
41
Polycarpou et al. Immunology of Erythema Nodosum Leprosum
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 233
patterns in leprosy patients during multiple drug therapy. Immunology (1998) 
94(2):197–206. doi:10.1046/j.1365-2567.1998.00485.x 
223. Mendonca VA, Costa RD, Lyon S, Penido RA, Borges VO, Bretas TL, et al. 
Plasma levels of chemokines during leprosy specific treatment. Acta Trop 
(2010) 113(2):151–4. doi:10.1016/j.actatropica.2009.10.010 
224. Nishimura M, Koeda A, Suzuki E, Shimizu T, Kawano Y, Nakayama 
M, et  al. Effects of prototypical drug-metabolizing enzyme inducers on 
mRNA expression of housekeeping genes in primary cultures of human 
and rat hepatocytes. Biochem Biophys Res Commun (2006) 346(3):1033–9. 
doi:10.1016/j.bbrc.2006.06.012 
225. Libert C, Dejager L. How steroids steer T cells. Cell Rep (2014) 7(4):938–9. 
doi:10.1016/j.celrep.2014.04.041 
226. Langereis JD, Oudijk EJ, Schweizer RC, Lammers JW, Koenderman 
L, Ulfman LH. Steroids induce a disequilibrium of secreted interleu-
kin-1 receptor antagonist and interleukin-1beta synthesis by human 
neutrophils. Eur Respir J (2011) 37(2):406–15. doi:10.1183/09031936. 
00170409 
227. Auttachoat W, Zheng JF, Chi RP, Meng A, Guo TL. Differential surface 
expression of CD18 and CD44 by neutrophils in bone marrow and spleen 
contributed to the neutrophilia in thalidomide-treated female B6C3F1 
mice. Toxicol Appl Pharmacol (2007) 218(3):227–37. doi:10.1016/j.taap. 
2006.11.019 
228. Kim BS, Kim JY, Lee JG, Cho Y, Huh KH, Kim MS, et al. Immune modula-
tory effect of thalidomide on T cells. Transplant Proc (2015) 47(3):787–90. 
doi:10.1016/j.transproceed.2014.12.038 
229. Hernandez Mde O, Fulco Tde O, Pinheiro RO, Pereira Rde M, Redner P, 
Sarno EN, et  al. Thalidomide modulates Mycobacterium leprae-induced 
NF-kappaB pathway and lower cytokine response. Eur J Pharmacol (2011) 
670(1):272–9. doi:10.1016/j.ejphar.2011.08.046 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Polycarpou, Walker and Lockwood. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License 
(CC BY). The use, distribution or reproduction in other forums is permitted, provided 
the original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
